PBN-PVT projections modulate negative affective states in mice

Ya-Bing Zhu^{1,5}, Yan Wang^{1,5}, Xiao-Xiao Hua^{2,5}, Ling Xu¹, Ming-Zhe Liu³, Rui Zhang¹, Peng-Fei Liu¹, Jin-Bao Li¹, Ling Zhang^{2,*}, Di Mu^{4,6,*}

¹Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China

²The First Rehabilitation Hospital of Shanghai, Tongji University School of Medicine, Shanghai 200090, China

³Department of Respiratory, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

⁴SUSTech Center for Pain Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China; Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China

⁵These authors contributed equally

⁶Lead Contact

*Correspondence to:

Ling Zhang, Ph.D., The First Rehabilitation Hospital of Shanghai, Tongji University School of Medicine, Shanghai 200090, China; Email: lizhang0808@tongji.edu.cn.

Di Mu, Ph.D., SUSTech Center for Pain Medicine, School of Medicine, Southern University of Science and Technology, Shenzhen 518055, China; Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201620, China; Email: damonmu@163.com or dimu08207@ustc.edu.

Abstract

Long-lasting negative affections dampen enthusiasm for life, and dealing with negative affective states is essential for individual survival. The parabrachial nucleus (PBN) and thalamic paraventricular nucleus (PVT) are critical for modulating affective states in mice. However, the functional roles of PBN-PVT projections in modulating affective states remain elusive. Here, we show that PBN neurons send dense projection fibers to the PVT and form direct excitatory synapses with PVT neurons. Activation of the PBN-PVT pathway induces robust behaviors associated with negative affective states without affecting nociceptive behaviors. Inhibition of the PBN-PVT pathway reduces aversion-like and fear-like behaviors. Furthermore, the PVT neurons innervated by the PBN are activated by aversive stimulation, and activation of PBN-PVT projections enhances the neuronal activity of PVT neurons in response to the aversive stimulus. Consistently, activation of PVT neurons that received PBN-PVT projections induces anxiety-like behaviors. Thus, our study indicates that PBN-PVT projections modulate negative affective states in mice.

Keywords: Parabrachial nucleus (PBN); thalamic paraventricular nucleus (PVT); affective states; anxiety; aversion.

Introduction

Threat and injury often induce defensive behaviors, such as flight, freezing, hiding (*Öhman and Mineka, 2001*), and negative affective states, such as fear and anxiety (*Jimenez et al., 2018*). Such behavioral adaptations and psychological responses are essential for animal survival, and understanding their mechanisms is of great interest. It is worth noting that the parabrachial nucleus (PBN) in the brainstem plays a critical role in encoding danger signals and promoting affective behavior states to limit harm in response to potential threats (*Campos et al., 2018*).

The PBN receives the majority of the ascending inputs from the spinal cord

(*Todd, 2010*), and PBN neurons respond robustly to nociception, food neophobia, hypercapnia, and threat to maintain homeostasis in stressful circumstances (*Campos et al., 2018; Kaur et al., 2013*). The PBN relays this information (visceral malaise, taste, temperature, pain, itch) to brain areas, such as the hypothalamus, central amygdala (CeA), thalamus, insular cortex (IC), and periaqueductal gray (PAG), to participate in diverse physiological processes (*Chiang et al., 2019; Palmiter, 2018; Saper, 2016*). A recent study found that subpopulations of the PBN have distinct projection patterns and functions (*Chiang et al., 2020*). Neurons in the dorsal division of the PBN projecting to the ventromedial hypothalamus (VMH) and PAG mediate escape behaviors. In contrast, neurons in the external lateral division of the PBN projecting to the bed nucleus of the stria terminalis (BNST) and the CeA mediate aversion and avoidance memory (*Chiang et al., 2020*). Optogenetic manipulation of specific outputs from PBN accomplishes distinct functions (*Bowen et al., 2020*). In the thalamus, the intralaminar thalamus nucleus (ILN) is the downstream target of PBN neurons that receive spinal cord inputs, and this ILN pathway participates in nociception processing (*Deng et al., 2020*). In addition to the ILN, the thalamic paraventricular nucleus (PVT) is another primary target of projections from the PBN nucleus in the thalamus (*Chiang et al., 2020*).

The PVT has been implicated in a range of affective behaviors (*Hsu et al., 2014*). The functional roles of the PVT include modulation of a diverse array of processes, such as arousal (*Ren et al., 2018*), drug addiction (*Zhu et al., 2016*), reward seeking (*Do-Monte et al., 2017; Engelke et al., 2021*), stress (*Beas et al., 2018; Gao et al., 2020*), associative learning and memory retrieval (*Penzo et al., 2015; Do-Monte et al., 2015; Zhu et al., 2018; Keyes et al., 2020*). The PVT receives a significant amount of input from the brainstem, hypothalamus, and prefrontal cortical areas and projects to the infralimbic cortex, nucleus accumbens (NAc), BNST, and CeA (*Kirouac, 2015; Vertes et al., 2015*). The convergent signals include arousal from the hypothalamus (*Ren et al., 2018*),

emotional saliency from the prefrontal cortex (Yamamuro *et al.*, 2020), and stress responsivity from the locus coeruleus (LC) (Beas *et al.*, 2018), which might help promote appropriate behavioral responses to environmental challenges. However, despite substantial improvements in our understanding of the neurocircuitry of the PVT, the functional role of PBN-PVT projections remains mostly unknown.

In this study, we used viral tracing and electrophysiology to dissect the anatomical and functional connections between the PBN and the PVT. By using optogenetic and pharmacogenetic approaches, we then demonstrated that PBN-PVT projections modulate negative affective states in mice.

Results

Functional connectivity pattern of PBN-PVT projections

Although it has been shown that the PVT receives input from the PBN (Chiang *et al.*, 2020; Li and Kirouac, 2012), the detailed morphology of PBN-PVT projections and whether these two nuclei form direct functional synapses remain unknown. To examine the synaptic connectivity between the PBN and the PVT, we injected AAV2/8-hSyn-ChR2-mCherry virus into the PBN and employed whole-cell patch-clamp recording. There were dense projection fibers in the PVT (Figure 1A–C) and precisely time-locked action potentials induced by brief laser pulses in PBN ChR2⁺ neurons (5 Hz, 10 Hz, and 20 Hz; Figure 1G). We found that optogenetic activation of PBN projection fibers evoked excitatory postsynaptic currents (EPSCs) in 34 of 52 PVT neurons. The medial PVT (bregma: -0.94 to -1.82 mm; 18 of 25 cells, 72.0%) and posterior PVT (bregma: -1.82 to -2.3 mm; 14 of 21 neurons, 66.7%) showed higher connectivity than the anterior PVT (bregma: -0.22 to -0.94 mm; 2 of 6 cells, 33.3%; Figure 1D–F). The average amplitude of the light-evoked EPSCs was 103.4 ± 11.93 pA (Figure 1H). Moreover, the latency of EPSCs was short with small jitter (Figure 1I–J), indicating monosynaptic connections between the PBN and PVT. Consistently, the EPSCs were sensitive to the Na⁺ channel

blocker tetrodotoxin (TTX, 1 μ M) and were rescued by the K⁺ channel blocker 4-aminopyridine (4-AP, 100 μ M). The EPSCs were further blocked by the AMPA receptor antagonist NBQX (10 μ M), confirming the monosynaptic glutamatergic innervation of PVT neurons by PBN neurons (*Figure 1K–L*). In addition, we also observed light-evoked inhibitory postsynaptic currents (IPSCs) in only 4 of 52 PVT neurons (less than 30 pA). Thus, these results indicate that most monosynaptic connections between PBN and PVT are glutamatergic.

Next, we asked what are the distribution pattern and molecular identity of PBN-PVT neurons. We injected retroAAV2/2-hSyn-Cre virus into the PVT of *Rosa26-tdTomato* mice, which could retrogradely label projection neurons in the PBN (*Figure 1M–P*). We found that tdTomato⁺ neurons were bilaterally located in the lateral PBN (55 $\pm$ 6 neurons, n = 4 mice) and rarely in the medial PBN (8 $\pm$ 1 neurons; *Figure 1O–Q*). These results indicate that most PVT inputs originate in the lateral aspect of the PBN. We then performed tdTomato staining and in situ hybridization with *Slc17a6* (Vglut2) probe, and found that approximately 94.4% of tdTomato⁺ neurons expressed *Slc17a6* mRNA (Vglut2⁺, *Figure 1R–U*). We also examined several markers for subpopulations of PBN neurons, including tachykinin 1 receptor (*Tacr1*), tachykinin 1 (*Tac1*), prodynorphin (*Pdyn*), and calcitonin gene-related peptide (CGRP). We found that tdTomato⁺ neurons were only partially colabeled with *Tacr1* mRNA (38.0%), *Tac1* mRNA (6.4%), or *Pdyn* mRNA (23.0%) and not with CGRP protein (*Figure 1–figure supplement 1*). These results indicate that the majority of PBN-PVT neurons are glutamatergic neurons, and most of these neurons are not labeled by *Tacr1*, *Tac1*, *Pdyn*, or CGRP.

To examine the collateral projections from the PVT-projecting PBN glutamatergic neurons, we injected AAV2/8-EF1 α -DIO-EGFP virus into the PBN of *Slc17a6*^{tm2(*cre*)*Low*} (also called Vglut2-ires-Cre) mice (*Figure 1–figure supplement 2A*). Robust expression of AAV2/8-EF1 α -DIO-EGFP was found in both the lateral and medial PBN (*Figure 1–figure supplement 2B–D*). It is worth

noting that the density of EGFP⁺ fibers was higher in the middle and posterior PVT (*Figure 1–figure supplement 2E–H*), considering the notion that the posterior PVT is particularly sensitive to aversion (*Gao et al., 2020*). We also found collateral projections from PBN-PVT neurons in the BNST, lateral hypothalamus (LH), paraventricular nucleus of the hypothalamus (PVN), and PAG but not in the CeA or VMH (*Figure 1–figure supplement 3*).

Optogenetic activation of PBN-PVT projections induces anxiety-like behaviors and aversion-like behaviors

To examine the functional role of PBN-PVT projections in modulating affective behaviors, we injected AAV2/9-EF1 α -DIO-ChR2-mCherry virus or AAV2/9-EF1 α -DIO-mCherry virus bilaterally into the PBN of Vglut2-ires-Cre mice and implanted optic fibers above the PVT to selectively activate PBN-PVT projections (*Figure 2A*). Four weeks after surgery, we found robust expression of ChR2-mCherry (*Figure 2B–C, Figure 2–figure supplement 1A*) or mCherry (*Figure 2–figure supplement 1C*) in bilateral PBN neurons and axon terminals in the PVT (*Figure 2D, Figure 2–figure supplement 1B, Figure 2–figure supplement 1D*).

We performed a 15-minute optogenetic manipulation in the open field test (OFT; 0–5 minute laser OFF, 5–10 minute laser ON, 10–15 minute laser OFF; *Figure 2E*). Optogenetic activation (473 nm, 20 Hz, 5 mW, 5 ms) of the efferents from the PBN to the PVT elicited instant running behavior along the chamber wall with a significantly increased velocity (*Figure 2F–H, Figure 2–video 1*). The activation of PBN-PVT projections also reduced the center time compared with that of the control mice (*Figure 2I*). It is worth noting that the velocity returned to normal once the laser was off, but the time spent in the center was still lower than that of the control group during the 5 minutes after stimulation. These results indicate that anxiety could last for at least several minutes after acute activation of PBN-PVT projections. Although the speed increased during the laser ON period, the immobility time of the ChR2 mice

during the laser ON period was also increased (*Figure 2-figure supplement 2A*). Therefore, the distance during the laser ON period and the total distance in 15 minutes were not changed (*Figure 2-figure supplement 2B*).

To provide a more detailed profile of behavior in the OFT, we further divided the laser ON period (5–10 minutes) into five one-minute periods and analyzed the velocity, immobility time, center time, distance, and jumping (*Figure 2-figure supplement 2C–G*). We found that the velocity and immobility time were increased, and the center time was decreased in the ChR2 mice during most periods (*Figure 2-figure supplement 2C–E*). Furthermore, we observed that the distance and jumping behaviors were increased mainly in the first one-minute period in ChR2 mice (*Figure 2-figure supplement 2F–G*). This detailed analysis indicates that optogenetic activation of PBN-PVT projections could induce brief and robust running, jumping behaviors, and persistent anxiety-like behaviors, such as less time spent in the center.

In addition to anxiety, another critical component of negative affective states is aversion. Therefore, we used the real-time place aversion (RTPA) test to explore the function of optogenetic activation of PBN-PVT projections in modulating aversion (*Figure 2J*). We found that the activation of PBN-PVT projections reduced the time spent in the laser-paired chamber, and the aversion disappeared when the laser was off (*Figure 2K–M, Figure 2-video 2*). We also used a prolonged conditioning protocol that mimics drug-induced conditioned place aversion (*Figure 2-figure supplement 2H*). We found that prolonged activation of PBN-PVT projections did not display aversion in the postconditioning test (*Figure 2-figure supplement 2I*).

To further confirm this instant aversion phenomenon, we subjected mice to the cue-dependent optogenetic conditioning test (*Figure 2N*). A 30-second auditory conditioning stimulus (CS) co-terminated with 30 seconds of synchronous optogenetic activation of PBN-PVT projections (laser stimulus, LS) in this test. Activation of the PBN-PVT projections induced significant freezing behavior during 6 CS-LS pairings (*Figure 2O*). However, the freezing

behavior to the same context or to the auditory cue in a novel context disappeared on the second day (*Figure 2P–Q*). These results indicate that optogenetic activation of PBN-PVT projections induces instant aversion and freezing but do not drive associative fear memory formation.

Pharmacogenetic activation of PBN-PVT neurons induces anxiety-like behaviors and freezing behaviors

To further confirm the effects of activating the PBN-PVT pathway, we also used retrograde viral tracing and pharmacogenetic manipulation. We first injected retroAAV2/2-hSyn-Cre virus into the PVT and AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or control virus bilaterally into PBN to specifically transduce PBN-PVT neurons with the hM3Dq, a designer receptor exclusively activated by designer drugs (*Figure 3A*) (*Armbruster et al., 2007*). PBN-PVT neurons could be activated by intraperitoneal injection of clozapine N-oxide dihydrochloride (CNO; *Figure 3B–D*). The region of virus expression in the PBN is shown in *Figure 3–figure supplement 1*. Consistent with the optogenetic activation results, pharmacogenetic activation of PBN-PVT neurons reduced the center time, increased immobility time, and reduced the travel distance in the OFT (*Figure 3E–I*). At the same time, the velocities were not significantly different (*Figure 3J*). We also found that activation of PBN-PVT neurons did not affect motor ability in the rotarod test (*Figure 3–figure supplement 2G*). In addition, pharmacogenetic activation of PBN-PVT neurons decreased exploration time of open quadrants in the elevated zero maze (EZM; *Figure 3K–L*), further suggesting that activation of PBN-PVT neurons induces anxiety-like behaviors.

We further evaluated freezing behaviors in the fear conditioning chamber and found that pharmacogenetic activation of PBN-PVT neurons induced more freezing behaviors (*Figure 3M–N*). Although activation of PBN-PVT neurons induced significant anxiety-like behavior, it did not affect the depressive-like behaviors evaluated by the tail suspension test (TST; *Figure 3–figure*

supplement 2A) or the forced swimming test (FST; *Figure 3-figure supplement 2B*). Previous studies have revealed that the PBN receives direct projections from the spinal cord and plays a vital role in pain processing (*Deng et al., 2020; Sun et al., 2020*). We then assessed whether pharmacogenetic activation of PBN-PVT neurons affected nociceptive behaviors. By performing the von Frey test and Hargreaves test, we found that the basal nociceptive thresholds were not affected after pharmacogenetic activation of PBN-PVT neurons (*Figure 3-figure supplement 2C-D*). Given the distinct mechanisms between the reflexive and coping responses induced by nociceptive stimulation (*Huang et al., 2019*), we injected formalin into the paw to induce inflammatory pain. We found that activation of PBN-PVT neurons did not affect formalin-evoked licking behaviors (*Figure 3-figure supplement 2E-F*). These results indicate that activating the PBN-PVT pathway induces anxiety-like and freezing behaviors but not nociceptive behaviors.

Inhibition of PBN-PVT projections reduces aversion-like behaviors and freezing behaviors

We next asked whether inhibition of PBN-PVT projections could modulate negative affective states. We first injected AAV2/9-EF1 α -DIO-NpHR3.0-EYFP virus or AAV2/8-EF1 α -DIO-EGFP virus bilaterally into the PBN and implanted optic fibers into the PVT of Vglut2-ires-Cre mice (*Figure 4A-C, Figure 4-figure supplement 1*). We used 2-methyl-2-thiazoline (2-MT), a widely used odorant molecule that can generate innate fear-like freezing responses in rodents (*Isosaka et al., 2015*), to induce a fear-like state. We found that 589 nm laser-induced inhibition of PBN-PVT projections reduced the aversion caused by 2-MT exposure (*Figure 4D-F*) and increased the moving duration (*Figure 4G*). We also observed that inhibition of PBN-PVT projections increased the time spent in the 2-MT zone in the OFT (*Figure 4H-I*). In addition to 2-MT, footshock is another paradigm that induces robust freezing behaviors. We found that constant inhibition of PBN-PVT projections reduced

footshock-induced freezing behaviors (*Figure 4J–K*).

We also examined whether inhibition of the PBN-PVT projection affects aversive memory acquisition or retrieval (*Figure 4-figure supplement 2A*). We briefly suppressed the activity of PBN-PVT projections during footshock stimulation and found that freezing levels during the condition were not changed (*Figure 4-figure supplement 2B*). We further compared freezing levels in contextual and cue tests without or with laser and found that aversive memory retrieval was not affected either (*Figure 4-figure supplement 2C–D*). In addition, we performed optogenetic inhibition of PBN-PVT neurons and observed similar phenomena (*Figure 4-figure supplement 3*). Thus, these results indicate that inhibition of the PBN-PVT pathway reduces aversion-like behaviors and footshock-induced freezing behaviors without affecting aversive memory acquisition or retrieval.

PBN input shapes PVT neuronal responses to aversive stimulation

To further examine the activity of the PVT in response to aversive stimulation, we performed the *in vivo* fiber photometry and found that calcium signals of PVT neurons were increased after the footshock and air puff (*Figure 5-figure supplement 1*). In addition, we injected AAV2/1-hSyn-Cre virus, which could anterogradely label downstream neurons (*Zingg et al., 2017*), into the PBN of *Rosa26-tdTomato* mice (*Figure 5A*). The distribution pattern of PVT neurons that received PBN-PVT projection fibers (hereafter referred to as PVT_{PBN} neurons) was shown in *Figure 5B–D*. We used Fos as a marker to assess the activity change in 2-MT-treated mice and footshock-treated mice. The percentage of Fos⁺tdTomato⁺ neurons/tdTomato⁺ neurons in the PVT was significantly increased in the mice treated with aversive stimuli compared with that of control mice (*Figure 5E–H*), confirming that the PVT_{PBN} neurons could be activated by aversive stimuli.

The next question is whether PBN-PVT projections modulate the neuronal activity of PVT neurons in response to aversive stimuli. We first injected

AAV2/9-EF1 α -DIO-ChR2-mCherry virus into the PBN and performed dual Fos staining (Seike *et al.*, 2020), detecting *fos* mRNA and Fos protein induced by two episodes of stimulation (Figure 6-figure supplement 1A). We found that there was a broad overlap between optogenetic stimulation-activated neurons (expressing the Fos protein) and footshock-activated neurons (expressing the *fos* mRNA) (Figure 6-figure supplement 1B-E).

Then, we injected AAV2/9-EF1 α -DIO-ChR2-mCherry virus into the PBN and implanted the optoelectrode into the PVT of Vglut2-ires-Cre mice (Figure 6A). We first recorded the spiking signals in response to 10 sweeps of 2-second laser pulse trains (20 Hz, 5 mW, 5 ms). Then, we recorded the spiking signals in response to 20 sweeps of 2-second footshock (0.5 mA) without laser in the odd number sweeps or with laser in the even number sweeps (Figure 6A). We found that laser or footshock (without laser) increased firing rates in 22 or 28, respectively, of 40 neurons (Figure 6B-C). There was also a broad overlap between laser-activated and footshock-activated neurons (Figure 6D). This result was consistent with the dual Fos staining result, suggesting that PVT_{PBN} neurons were activated by aversive stimulation. We also analyzed the response latency of laser-activated neurons and footshock-activated neurons (Figure 6-figure supplement 2A-D). The median response latency of 22 laser-activated neurons was 10 ms, suggesting that monosynaptic inputs from PBN could increase the PVT activity.

Next, we analyzed the firing rates of PVT neurons during footshock with laser sweeps and footshock without laser sweeps (Figure 6E-G). We found that the footshock stimulus with laser-activated 30 of 40 neurons (Figure 6H) and increased the overall firing rates of 40 neurons compared with the footshock without laser result (Figure 6I). These results indicate that activation of PBN-PVT projections could enhance PVT neuronal responses to aversive stimulation.

Pharmacogenetic activation of PVT_{PBN} neurons induces anxiety-like

behaviors

We next investigate the functional role of PVT_{PBN} neurons in modulating negative affective states. We injected AAV2/1-hSyn-Cre virus bilaterally into the PBN and injected AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or control virus into the PVT to activate PVT_{PBN} neurons (*Figure 7A*). The majority of the PVT_{PBN} neurons could be activated by CNO in the hM3Dq-expressing mice but not the control mice, as demonstrated by the Fos staining (*Figure 7B–D*). We found that pharmacogenetic activation of PVT_{PBN} neurons reduced the center time (*Figure 7E–F*). Similarly, the time spent in open quadrants was decreased and overall immobility time was increased in the EZM after activation of PVT_{PBN} neurons (*Figure 7G–I*). We did not observe obvious nociception-related behaviors, such as forelimb wiping, hindlimb flinching, licking, or biting, after activation of PVT_{PBN} neurons. These results indicate that pharmacogenetic activation of PVT_{PBN} neurons induces anxiety-like behaviors.

Furthermore, we examined the anatomic distribution of terminals of PVT_{PBN} neurons. We labeled PVT_{PBN} neurons in WT mice by injecting AAV2/1-hSyn-Cre virus into the PBN and AAV2/8-EF1 α -DIO-EGFP virus into the PVT (*Figure 7-figure supplement 1A–B*). We found that PVT_{PBN} neurons sent projections to several brain areas, in particular the NAc, BNST, and CeA (*Figure 7-figure supplement 1B–H*), which was similar to early tracing research on PVT efferent projections (*Li and Kirouac, 2008*).

Discussion

In this study, we employed viral tracing and electrophysiology to confirm the monosynaptic excitatory connectivity between the PBN and the PVT. Optogenetic or pharmacogenetic activation of the PBN-PVT pathway induced anxiety-like, aversion-like, and fear-like behaviors. Optogenetic inhibition of the PBN-PVT pathway could partially reduce 2-MT-induced aversive behaviors as well as footshock-induced freezing behaviors. The activity of PVT neurons was increased with the presentation of several aversive stimuli and could be further

increased by activation of PBN-PVT projections. Consistently, activation of PVT_{PBN} neurons induced anxiety-like behaviors. Taken together, our results reveal the functional role of PBN-PVT projections in modulating negative affective states in mice.

PBN efferents and PBN-PVT monosynaptic excitatory projections

The PBN is a critical hub receiving sensory information from the spinal cord (*Todd, 2010*). The widespread distribution of PBN efferents contributes to different aspects of behavioral and physiological responses. Previous studies have shown that CGRP-expressing neurons in the PBN project to the CeA and contribute to the affective dimension of pain. In contrast, non-CGRP neurons may transmit sensory pain information (*Han et al., 2015*). The projections from the PBN to the VMH or PAG are involved in producing escape behaviors to avoid injury, while the projections from the PBN to the BNST or CeA participate in facilitating aversive memory (*Chiang et al., 2020*). PBN neurons, which receive projections from the spinal cord, form strong functional synaptic connections with ILN neurons but not CeA neurons to process nociceptive signals (*Deng et al., 2020*). The PVT, which is located in the midline of the brain, is an important area that participates in the processing of affective states (*Kirouac, 2015*). Although recent research has reported that projecting fibers from the PBN were found in the PVT (*Chiang et al., 2020*), remarkably little is known about the connectivity information and function of these PBN-PVT projections.

Since we injected the constitutively expressed ChR2 virus into the PBN, some neurons in the LC (which is medial to the PBN) might be infected. LC neurons express type 1 vesicular glutamate transporter (Vglut1) and also project to the PVT (*Beas et al., 2018*). Although PBN-PVT projections comprise the major portion of the projections, there is still potential contamination from LC-PVT projections. We also observed a small portion of inhibitory connections between the PBN and the PVT by performing slice

recording experiments. These results are consistent with a previous study showing that GABAergic neurons in the PBN also send sparse projections to the PVT (*Chiang et al., 2020*). We speculate that this PBN-PVT GABAergic pathway might play an opposite role in modulating negative affective states. Further in situ hybridization results confirmed that the PBN-PVT neurons were mainly glutamatergic neurons expressing *Slc17a6* mRNA. These results suggest that the majority of the PBN-PVT projections appeared to be excitatory. Further optoelectrode experiment results also confirmed that firing rates of some PVT neurons could be directly increased by monosynaptic inputs from PBN.

We also found that the connectivity and density of glutamatergic PBN projection fibers were higher in the middle and posterior PVT (pPVT). These results are consistent with various studies supporting the idea that the pPVT is a particularly sensitive region of the PVT to aversive stimuli (*Gao et al., 2020; Beas et al., 2018; Barson et al., 2020*).

PBN-PVT projections modulate negative affective states

We found that activation of PBN-PVT projections or PBN-PVT neurons induced anxiety-like behaviors and fear-like behaviors in the OFT and EZM. We observed that mice displayed robust running and jumping behaviors mainly in the first minute of optogenetic manipulation, and these phenomena were not observed in the pharmacogenetic experiment. These might have been caused by the instantly increased activity of PBN-PVT projections induced by optogenetic manipulation. Mice might display “fight or flight” during sudden affective state transitions. The pharmacogenetic approach takes several minutes and gradually enhances neural activity, and the resulting affective states change in a relatively mild way. We also observed that anxiety-like behaviors in the OFT still existed several minutes after optogenetic activation of PBN-PVT projections. However, in the RTPA test, aversion appeared when the laser was on and disappeared when the laser was off,

indicating that aversion was transient and could not be translated to associative learning. This was further confirmed by the prolonged conditioned place aversion test and cue-dependent optogenetic conditioning test. These results suggest that activation of PBN-PVT projections induces instant negative affective states but does not drive associative fear memory formation.

The selective optogenetic inhibition of PBN-PVT projections or PBN-PVT neurons could reduce aversion-like and fear-like behaviors. To better examine the behavioral changes, we performed a 10-minute test in 2-MT and footshock experiments. We used a relatively long-term protocol in optogenetic inhibition experiments (10 minutes of constant laser stimulation). Such long-term inhibition protocols have been used in other studies (*Zhou et al.*, 2019; *Sun et al.*, 2020). We also performed the classic fear conditioning test and found that inhibition of PBN-PVT projections did not affect associative fear memory formation or retrieval, suggesting that PBN-PVT projections mainly promote aversion but do not facilitate negative associations.

Our calcium imaging and Fos staining results indicate that PVT neurons are activated after exposure to aversive stimuli, consistent with a previous study (*Zhu et al.*, 2018). The dual Fos staining experiment and optoelectrode experiments confirmed a broad overlap between laser-activated and footshock-activated neurons. The median response latency of laser-activated PVT neurons was 10 ms, indicating monosynaptic inputs from PBN could directly activate a part of PVT neurons. We also observed that some neurons had relatively long latency (from 20 to 150 ms). That might be caused by cumulative effects of monosynaptic inputs or antidromic activation of PBN and multi-synaptic activation of other PVT inputs that are innervated by the PBN. Further analysis showed that activation of PBN-PVT projections enhanced the overall firing rates of PVT neurons in response to footshock. These results suggest that the activation of PBN-PVT projections could enhance neuronal activity in response to aversive stimulation.

Previous studies have reported that activation of the PBN-CeA pathway

was sufficient to drive behaviors associated with negative affective states (Bowen *et al.*, 2020; Cai *et al.*, 2018; Han *et al.*, 2015), enable associative learning, and generate aversive memory (Chiang *et al.*, 2020). Distinct from PBN-CeA projections, we found that activation of PBN-PVT projections induced only transient aversion-related behaviors, and inhibition of PBN-PVT projections did not affect fear memory acquisition or retrieval. A study reported that only a few fluoro-gold (FG)/tetramethylrhodamine-dextran (TMR) double-labeled neurons were sparsely distributed in the PBN of mice injected with FG into the PVT and TMR into the CeA (Liang *et al.*, 2016). Our results also showed few collateral projecting fibers in the CeA or VMH from PBN-PVT neurons. These results suggested that the PBN-PVT pathway and the PBN-CeA pathway are two parallel pathways originating from distinct efferent neurons within the PBN that perform distinct functions.

Recently, Chiang *et al.* found two major efferent pathways from the lateral PBN: one originating from the dorsal division of lateral PBN collateralizes the VMH and PAG and a second arising from the external lateral division of lateral PBN that collateralize to the BNST and CeA. They suggested that activation of the first pathway generates the aversive memory, and activation of the second one drives escape behaviors (Chiang *et al.*, 2020). In our study, the results indicate that the PBN-PVT pathway arises from both dorsal and external lateral divisions of lateral PBN and collateralizes the BNST, LH, PVN, and PAG but not the CeA or VMH. According to the location of originated PBN neurons and collateral projection pattern, we speculated that the PBN-PVT efferent pathway is different from both PBN-VMH/PAG pathway and PBN-BNST/CeA pathway. Since there were broad collateral projection fibers in BNST, PAG, and other brain regions, the possibility of antidromic effects following photoactivation of PBN terminals in PVT should be considered.

The tracing results showed that PVT_{PBN} neurons projected to multiple brain areas, particularly the NAc, BNST, and CeA. The BNST and CeA have been previously implicated in negative affective behaviors (Jennings *et al.*, 2013;

Tye et al., 2011). Previous studies have shown that the activation of PVT-CeA projections induced place aversion, and the effect persisted the next day in the absence of photostimulation (*Do Monte et al., 2017*). Similarly, long-term depression (LTD)-like stimulation of PVT-CeA projections or inhibition of the same circuit induced a persistent attenuation of fear responses (*Chen and Bi, 2019; Do Monte et al., 2015; Penzo et al., 2015*). These results revealed a critical role of PVT-CeA projections in aversive memory formation. In our study, we found that PBN-PVT projections were not crucial for aversive memory formation. The possible reason might be that manipulation of PVT-CeA projections induced direct excitatory inputs to the CeA, and the inputs were strong enough for aversive memory formation. However, activation of PBN-PVT projections might not induce enough excitatory inputs to the CeA via the disynaptic connection.

A previous study also found that the PVT mediates descending pain facilitation underlying persistent pain conditions via the PVT-CeA-PAG circuit (*Liang et al., 2020*). Different downstream pathways of PVT_{PBN} neurons might have different functions, and deciphering the circuit mechanisms needs further examination.

The potential role of PBN-PVT projections in depression and pain

It is worth noting that although the pharmacogenetic activation of PBN-PVT neurons induced anxiety-like behaviors and fear-like behaviors in hM3Dq group mice, no depression-like symptoms were observed in the TST and FST. On the other hand, chronic pain models, such as the partial sciatic nerve ligation model, spared nerve injury model, and complete Freund's adjuvant model, generally induce anxiety and depression at least 3–4 weeks after surgery in mice (*Dimitrov et al., 2014; Zhou et al., 2019*). Our study collected behavioral data 30 minutes after a single dose of CNO injection. Different behavioral tests were performed at least three days apart to eliminate the residual CNO effects. We hypothesized that depression-like behaviors

might be observed if we repeatedly activated PBN-PVT projections for weeks. However, whether PBN-PVT projections are involved in depression is still unknown.

A recent study revealed that PBN neurons convey nociceptive information from the spinal cord to the ILN, which is relatively close to the PVT (Deng *et al.*, 2020). In our results, we carefully checked the virus expression and optic fiber locations. We found that pharmacogenetic activation of PBN-PVT neurons did not affect basal nociceptive thresholds or formalin-induced licking behaviors. Moreover, no obvious nociception-related behaviors were found through specific manipulations of the PBN innervated PVT neurons, which suggests that PBN-PVT projections might not be involved in nociceptive information processing.

In summary, we identified the functional role of PBN-PVT projections in modulating negative affective states. Our study paves the way for further deciphering the distinct roles of the PBN neural circuit in affective behaviors.

Acknowledgements

We thank Dr. Yan-Gang Sun for comments on the manuscript and for providing Vglut2-ires-Cre mice. We thank Dr. Hua-Tai Xu for providing *Rosa26-tdTomato* mice. We thank all the lab members of D.M. for their helpful discussion. This work was supported by the National Natural Science Foundation of China (No. 31900717, 31571086), the Shanghai Sailing Program (19YF1438700 to D.M.), the Young Elite Scientists Sponsorship Program of China Association for Science and Technology (2019QNRC001 to D.M.).

Materials and methods

Key Resources Table				
Reagent type (species) or	Designation	Source or reference	Identifiers	Additional information

resource				tion
Genetic reagent (M. musculus)	<i>B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (Ai9)</i>	Jackson Laboratory	Stock#: 007909 RRID:MGI:3813511	Dr. Hua-Tai Xu (Institute of Neuroscience, Chinese Academy of Sciences)
Genetic reagent (M. musculus)	<i>STOCK Slc17a6tm2(cre)Lowl/J (Vglut2-ires-Cre)</i>	Jackson Laboratory	Stock#: 016963 RRID:MGI:5300532	Dr. Yan-Gang Sun (Institute of Neuroscience, Chinese Academy of Sciences)
Genetic reagent (Dependoparvovirus)	AAV2/8-hSyn-ChR2-mCherry	Obio Technology	Cat#: AG26976	4×10^{12} v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/8-EF1 α -DIO-EGFP	Taitool Bioscience	Cat#: S0270	4×10^{12} v.g./mL
Genetic reagent (Dependoparvovirus)	retroAAV2/2-hSyn-Cre	Taitool Bioscience	Cat#: S0278-2RP-H20	4×10^{12} v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/9-EF1 α -DIO-ChR2-mCherry	Taitool Bioscience	Cat#: S0170-9-L20	4×10^{12} v.g./mL

Genetic reagent (Dependoparvovirus)	AAV2/9-EF1 α -DIO-mCherry	Obio Technology	Cat#: AG20299	4x10 ¹² v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/9-hSyn-DIO-hM3Dq-mCherry	BrainVTA	Cat#: PT-0019	4x10 ¹² v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/9-EF1 α -DIO-NpHR3.0-EYFP	Obio Technology	Cat#: AG26966	4x10 ¹² v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/8-hSyn-GCaMP6s	Taitool Bioscience	Cat#: S0225-8	4x10 ¹² v.g./mL
Genetic reagent (Dependoparvovirus)	AAV2/1-hSyn-Cre	Taitool Bioscience	Cat#: S0278-1-H50	1.5x10 ¹³ v.g./mL
Sequence-based reagent	RNAscope Probe- <i>fos</i> -C2	Advanced Cell Diagnostics	Cat#: 316921-C2	
Sequence-based reagent	RNAscope Probe- <i>Tac1</i> -C2	Advanced Cell Diagnostics	Cat#: 410351-C2	
Sequence-based reagent	RNAscope Probe- <i>Tacr1</i> -C2	Advanced Cell Diagnostics	Cat# 428781-C2	
Sequence-based reagent	RNAscope Probe- <i>Pdyn</i>	Advanced Cell Diagnostics	Cat#: 318771	
Sequence-based reagent	RNAscope Probe- <i>Slc17a6</i> -C2	Advanced Cell Diagnostics	Cat#: 319171-C2	
Antibody	Anti-Fos (Rabbit polyclonal)	Abcam	Cat#: ab190289, RRID:AB_2737414	IF(1:4000)

Antibody	Anti-CGRP (Goat polyclonal)	Abcam	Cat#: ab36001, RRID:AB_725807	IF(1:1000)
Antibody	Anti-DsRed (Goat polyclonal)	Takara Bio	Cat#: 632496, RRID:AB_10013483	IF(1:500)
Antibody	Alexa Fluor 488 AffiniPure Donkey Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch Labs	Cat#: 711-545-152, RRID:AB_2313584	IF(1:400)
Antibody	Cy3 AffiniPure Donkey Anti-Rabbit IgG (H+L)	Jackson ImmunoResearch Labs	Cat#: 711-165-152, RRID:AB_2307443	IF(1:400)
Antibody	Alexa Fluor 488 AffiniPure F(ab') ₂ Fragment Donkey Anti-Goat IgG (H+L)	Jackson ImmunoResearch Labs	Cat#: 705-546-147, RRID:AB_2340430	IF(1:400)
Commercial assay or kit	RNAscope Multiplex Fluorescent Reagent Kit v2	Advanced Cell Diagnostics	Cat#: 320293	
Software, algorithm	Image J	NIH		
Software, algorithm	LabState	Anilab		

537

538 **Animals**

539 Male C57Bl/6J wild-type mice, *Rosa26-tdTomato* mice (Jax Stock No: 007909,
540 gifted from Dr. Hua-Tai Xu, Institutes of Neuroscience, Chinese Academic of
541 Sciences), Vglut2-ires-Cre mice (Jax Stock No: 016963, gifted from Dr.
542 Yan-Gang Sun, Institutes of Neuroscience, Chinese Academic of Sciences)
543 were used. Animals were housed in standard laboratory cages in a
544 temperature (23-25°C)-controlled vivarium with a 12:12 light/dark cycle, free to
545 food and water. For tracing and behavioral experiments, the mice were
546 injected with the virus at 7–8 weeks old and performed the behavioral tests at
547 11–12 weeks old. For the electrophysiological experiments, the mice were

injected with the virus at 4–6 weeks old to accomplish the electrophysiological experiments at 7–9 weeks old. For *in vivo* fiber photometry and optoelectrode experiments, the mice were injected with the virus at 7–8 weeks old to accomplish the experiments at 10–11 weeks old. All animal experiment procedures were approved by the Animal Care and Use Committee of Shanghai General Hospital (2019AW008).

Stereotaxic surgery

Mice were anesthetized by vaporized sevoflurane (induction, 3%; maintenance, 1.5%) and head-fixed in a mouse stereotaxic apparatus (RWD Life Science Co.).

For electrophysiological experiments, the AAV2/8-hSyn-ChR2-mCherry virus (300 nL, 4×10^{12} v.g./mL, AG26976, Obio Technology) was injected into the PBN nucleus of WT mice in the stereotaxic coordinate: anteroposterior (AP) –5.2 mm, mediolateral (ML) +1.3 mm, and dorsoventral (DV) –3.4 mm.

For tracing studies, the AAV2/8-EF1 α -DIO-EGFP virus (300 nL, S0270, Taitool Bioscience) was injected into the PBN (mentioned above) of Vglut2-ires-Cre mice.

For the retrovirus injection surgery, the retrograde transport Cre recombinase retroAAV2/2-hSyn-Cre virus (150 nL, 4×10^{12} v.g./mL, S0278-2RP-H20, Taitool Bioscience) was injected in the *Rosa26-tdTomato* mice at two locations of PVT respectively: (1) AP –1.22 mm, ML 0 mm, DV –2.9 mm; (2) AP –1.46 mm, ML 0 mm, DV –2.9 mm.

For optogenetic activation of PVT-projecting PBN fibers, the AAV2/9-EF1 α -DIO-ChR2-mCherry virus (300 nL, 4×10^{12} v.g./mL, S0170-9-L20, Taitool Bioscience) or the AAV2/9-EF1 α -DIO-mCherry virus (300 nL, 4×10^{12} v.g./mL, AG20299, Obio Technology) was bilaterally injected into the PBN (mentioned above) of Vglut2-ires-Cre mice, and a 200 μ m diameter optic fiber was implanted over the PVT (AP –1.46 mm, ML 0 mm, DV –2.9 mm) with a 20° angle towards the midline.

For the pharmacogenetic activation of PBN-PVT neurons, the

retroAAV2/2-hSyn-Cre virus (150 nL, 4×10^{12} v.g./mL, S0278-2RP-H20, Taitool Bioscience) was injected into the PVT (AP -1.46 mm, ML 0 mm, DV -2.9 mm), the AAV2/9-hSyn-DIO-hM3Dq-mCherry virus (300 nL, 4×10^{12} v.g./mL, PT-0019, BrainVTA) or the control AAV2/9-EF1 α -DIO-mCherry virus was bilaterally injected into the PBN (mentioned above) of the WT mice.

For optogenetic inhibition of PVT-projecting PBN fibers, AAV2/9-EF1 α -DIO-NpHR3.0-EYFP virus (300 nL, 4×10^{12} v.g./mL, AG26966, Obio Technology) or the AAV2/8-EF1 α -DIO-EGFP virus was bilaterally injected into the PBN (mentioned above) of Vglut2-ires-Cre mice, and a 200 μ m diameter optic fiber was implanted over the PVT (AP -1.46 mm, ML 0 mm, DV -2.9 mm) with a 20° angle towards the midline.

For optogenetic inhibition of PBN-PVT neurons, retroAAV2/2-hSyn-Cre was injected into the PVT (AP -1.46 mm, ML 0 mm, DV -2.9 mm), AAV2/9-EF1 α -DIO-NpHR3.0-EYFP virus (300 nL, 4×10^{12} v.g./mL, AG26966, Obio Technology) or the AAV2/8-EF1 α -DIO-EGFP virus was bilaterally injected into the PBN of WT mice, the left optic fiber was implanted over the PBN vertically, and the right one was placed over the PBN with a 20° angle towards the midline.

For *in vivo* fiber photometry experiments, the AAV2/8-hSyn-GCaMP6s virus (200 nL, 4×10^{12} v.g./mL, S0225-8, Taitool Bioscience) was injected into the PVT nucleus (AP -1.46 mm, ML 0 mm, DV -2.90 mm) of the WT mice, the optic fiber was implanted above the PVT with a 20° angle towards the midline.

For optoelectrode experiments, the AAV2/9-EF1 α -DIO-ChR2-mCherry virus (300 nL, 4×10^{12} v.g./mL, S0170-9-L20, Taitool Bioscience) was bilaterally injected into the PBN (mentioned above) of Vglut2-ires-Cre mice. Three weeks later, the homemade optoelectrode was implanted into the PVT nucleus (AP -1.46 mm, ML 0 mm, DV -2.90 mm).

For pharmacogenetic activation of PVT_{PBN} neurons, the AAV2/1-hSyn-Cre virus (300 nL, 1.5×10^{13} v.g./mL, S0278-1-H50, Taitool Bioscience) was bilaterally injected into the PBN nucleus, the

AAV2/9-hSyn-DIO-hM3Dq-mCherry virus or the control AAV2/9-EF1 α -DIO-mCherry virus was injected into the PVT (AP –1.46 mm, ML 0 mm, DV –2.9 mm) of the WT mice.

The virus was infused through a glass pipette (10–20 μ m in diameter at the tip) at the rate of 50–100 nL/minute. The injection pipette was left in place for additional 8 minutes. After the surgeries, the skin was closed by the sutures, and the optic fiber was secured through the dental acrylic. Generally, tracing, electrophysiological or behavioral experiments were performed at least three weeks later. After experiments, histological analysis was used to verify the location of viral transduction and the optic fiber. The mice without correct transduction of virus or correct site of optic fiber were excluded for analysis.

Histology

Animals were deeply anesthetized with vaporized sevoflurane and transcardially perfused with 20 mL saline, followed by 20 mL paraformaldehyde (PFA, 4% in PBS). Brains were extracted and soaked in 4% PFA at 4°C for a minimum of 4 hours and subsequently cryoprotected by transferring to a 30% sucrose solution (4°C, dissolved in PBS) until brains were saturated (for 36–48 hours). Coronal brain sections (40 μ m) were cut using a freezing microtome (CM1950, Leica). The slices were collected and stored in PBS at 4°C until immunohistochemical processing. Nuclei were stained with DAPI (Beyotime, 1:10000) and washed three times with PBS.

The brain sections undergoing immunohistochemical staining were washed in PBS 3 times (10 minutes each time) and incubated in a blocking solution containing 0.3% TritonX-100 and 5% normal donkey serum (Jackson ImmunoResearch, USA) in PBS for 1 hour at 37°C. Sections were then incubated (4°C, 24 hours) with primary antibodies dissolved in 1% normal donkey serum solution. Afterward, sections were washed in PBS 4 times (15 minutes each time), then incubated with secondary antibodies for 2 hours at room temperature. After DAPI staining and washing with PBS, sections were mounted on glass microscope slides, dried, and covered with 50% glycerin

(ThermoFisher). The images were taken by the Leica Dmi8 microscope and the Leica SP8 confocal microscopy. The images were further processed by Fiji and Photoshop.

RNAscope in situ hybridization

Mice were anesthetized with isoflurane and rapidly decapitated. Brains were roughly dissected from perfused mice and post-fixed in 4% PFA at 4 °C overnight, dehydrated in 30% sucrose 1×PBS at 4 °C for 2 days. Mouse brains were embedded, cryosectioned in 15 µm coronal slices, and mounted on SuperFrost Plus Gold slides (Fisher Scientific). In situ hybridization was performed according to the protocol of the RNAscope Multiplex Fluorescent Reagent Kit v2 (Cat. No. 320293). Probes were purchased from Advanced Cell Diagnostics: *fos* (Cat. No. 316921-C2), *Tac1* (Cat. No. 410351-C2), *Tacr1* (Cat. No. 428781-C2), *Pdyn* (Cat. No. 318771), and *Slc17a6* (Cat. No. 319171-C2). Primary antibodies include rabbit anti-Fos (Abcam, Cat. No. ab190289, 1:4000), goat anti-CGRP (Abcam, Cat. No. ab36001, 1:1000), and rabbit anti-DsRed (Takara Bio, Cat. No. 632496, 1:500). All secondary antibodies were purchased from Jackson ImmunoResearch and used at 1:400 dilution. Secondary antibodies include Alexa 488 donkey anti-rabbit (Cat. No. 711-545-152), Cy3 donkey anti-rabbit (Cat. No. 711-165-152), and Alexa 488 donkey anti-goat (Cat. No. 705-546-147). Images were collected on a Leica fluorescence microscope and Leica LAS Software.

Fos induction

The mice were habituated for three days and performed gentle grabbing and holding for 1 minute, five times every day, to minimize background Fos expression.

To study the effect of pharmacogenetic manipulations on PBN-PVT neurons, we intraperitoneally injected 0.5 mg/kg clozapine N-oxide (CNO, Sigma). Ninety minutes later, the brain tissues were processed.

To assess 2-MT evoked Fos expression in the PVT, the mice were kept in a chamber with a floor covered with cotton containing 100 mL 1:1000 diluted

2-MT for 90 minutes. Then the mice were perfused.

To assess footshock-induced Fos expression in the PVT, we placed the mice into the chamber and delivered 30 times inevitable footshock (0.5 mA, 1 second) with a variable interval (averaging 60 seconds). After stimulation, animals were kept in the same apparatus for another 60 minutes, and brain tissues were then processed.

For the dual Fos experiments, we first delivered 20 minutes 473 nm laser pulses (20 Hz, 5 mW, 5ms) and left the mice to rest in the homecage for 60 minutes. Then we delivered the 20 minutes footshock stimulus (0.5 mA, 1 s, 30 times, variable interval) and perfused the mice.

Electrophysiology

The electrophysiological experiment was performed as previously described (*Mu et al., 2017*). Mice were anesthetized with sevoflurane and perfused by the ice-cold solution containing (in mM) sucrose 213, KCl 2.5, NaH₂PO₄ 1.25, MgSO₄ 10, CaCl₂ 0.5, NaHCO₃ 26, glucose 11 (300–305 mOsm). Brains were quickly dissected, and the coronal slices (250 μ m) containing the PBN or PVT were chilled in ice-cold dissection buffer using a vibratome (V1200S, Leica) at a speed of 0.12 mm/second. The coronal sections were subsequently transferred to a chamber and incubated in the artificial cerebrospinal fluid (ACSF, 34°C) containing (in mM): NaCl 126, KCl 2.5, NaH₂PO₄ 1.25, MgCl₂ 2, CaCl₂ 2, NaHCO₃ 26, glucose 10 (300–305 mOsm) to recover for at least 40 minutes, then kept at room temperature before recording. All solutions were continuously bubbled with 95% O₂/5% CO₂.

All experiments were performed at near-physiological temperatures (30–32°C) using an in-line heater (Warner Instruments) while perfusing the recording chamber with ACSF at 3 mL/minute using a pump (HL-1, Shanghai Huxi). Whole-cell patch-clamp recordings were made from the target neurons under IR-DIC visualization and a CCD camera (Retiga ELECTRO, QIMAGING) using a fluorescent Olympus BX51WI microscope. Recording pipettes (2–5 M Ω ; Borosilicate Glass BF 150-86-10; Sutter Instrument) were prepared by a

micropipette puller (P97; Sutter Instrument) and backfilled with potassium-based internal solution containing (in mM) K-gluconate 130, MgCl₂ 1, CaCl₂ 1, KCl 1, HEPES 10, EGTA 11, Mg-ATP 2, Na-GTP 0.3 (pH 7.3, 290 mOsm) or cesium-based internal solution contained (in mM) CsMeSO₃ 130, MgCl₂ 1, CaCl₂ 1, HEPES 10, QX-314 2, EGTA 11, Mg-ATP 2, Na-GTP 0.3 (pH 7.3, 295 mOsm). Biocytin (0.2%) was included in the internal solution.

In PBN-PVT ChR2 experiments, whole-cell recordings of PBN neurons with current-clamp ($I = 0$ pA) were obtained with pipettes filled with the potassium-based internal solution. The 473 nm laser (5 Hz, 10 Hz, 20 Hz pulses, 0.5 ms duration, 2 mW/mm²) was used to activate PBN ChR2 positive neurons. Light-evoked EPSCs and IPSCs of PVT neurons recorded with voltage-clamp (holding voltage of -70 mV or 0 mV) were obtained with pipettes filled with the cesium-based internal solution. The 473 nm laser (20 Hz paired pulses, 1 ms duration, 4 mW/mm²) was used to activate ChR2 positive fibers. The light-evoked EPSCs were completely blocked by 1 μ M TTX (tetrodotoxin), rescued by 100 μ M 4-AP (4-Aminopyridine), and blocked by 10 μ M NBQX (6-nitro-7-sulphamoylbenzo(f)quinoxaline-2,3-dione). NBQX and TTX were purchased from Tocris Bioscience. All other chemicals were obtained from Sigma.

Voltage-clamp and current-clamp recordings were carried out using a computer-controlled amplifier (MultiClamp 700B; Molecular Devices, USA). During recordings, traces were low-pass filtered at 4 kHz and digitized at 10 kHz (DigiData 1550B1; Molecular Devices). Data were acquired by Clampex 10.6 and filtered using a low-pass-Gaussian algorithm (-3 dB cut-off frequency = 1000 Hz) in Clampfit 10.6 (Molecular Devices).

Optogenetic manipulation

For activating the PBN-PVT projection, a 473 nm laser (20 Hz, 5 mW, 5 ms pulse duration) was delivered. For inhibition of the PBN-PVT projection and the PBN-PVT neurons, a constant laser (589 nm, 10 mW) was delivered.

Pharmacogenetic manipulation

All behavioral tests were performed 30 minutes after intraperitoneal injection of 0.5 mg/kg CNO in pharmacogenetic manipulation. Different behavior tests were performed at least three days apart.

Open field test

The open field test (OFT) was used to assess locomotor activity and anxiety-related behavior in an open field arena (40 x 40 x 60 cm) with opaque plexiglass walls. The mouse was placed in the center of the box and recorded by a camera attached to a computer. The movement was automatically tracked and analyzed by Anilab software (Ningbo AnLai, China). The total distance traveled, the total velocity, the total immobility time (the mice were considered to be immobile if immobility time lasts more than 1 s), and time spent in the center area (20 x 20 cm) were measured. The box was cleaned with 70% ethanol after each trial.

To assess the effect of optogenetic activation of the PBN-PVT projection, 15 minutes sessions consisting of 5 minutes pre-test (laser OFF), 5 minutes laser on test (laser ON), and 5 minutes post-test (laser OFF) periods. Laser (473 nm, 20 Hz, 5 mW, 5 ms) was delivered during the laser on phase.

To assess the effect of pharmacogenetic manipulations of PBN-PVT neurons on locomotor activity and affective behaviors, we recorded the movement 30 minutes after intraperitoneal (i.p.) injection with CNO.

To assess the effect of inhibition of the PBN-PVT projection on the aversive behaviors induced by 2-MT. One cotton ball containing 5 mL 2-MT (1:1000) solution was placed on the center of the upper left quadrant to disseminate fear-odor, then a constant laser (589 nm, 10 mW) was delivered during the 10 minutes test. The time spent in the 2-MT paired quadrant was calculated.

Elevated zero maze (EZM)

The EZM was an opaque plastic circle (60 cm diameter), which consisted of four sections with two opened and two closed quadrants. Each quadrant had a path width of 6 cm. The maze was elevated 50 cm above the floor. The

animals were placed into an open section facing a closed quadrant and freely explored the maze for 5 minutes.

Real-time place aversion (RTPA) test

Mice were habituated to a custom-made 20 x 30 x 40 cm two-chamber apparatus (distinct wall colors and stripe patterns) before the test. Each mouse was placed in the center and allowed to explore both chambers without laser stimulation for 10 minutes on Day 1. The movement was recorded for 10 minutes as a baseline. The mice performed a slight preference for the black chamber according to the fact the mice have innate aversive to brightly illuminated areas. On Day 2, 473 nm laser stimulation (20 Hz, 5 mW, 5 ms) was automatically delivered when the mouse entered or stayed in the black chamber and turned off when the mouse exited the black chamber for 10 minutes. Finally, the mouse was allowed to freely explore both chambers without laser stimulation for another 10 minutes. The RTPA location plots and total time on the stimulated side were recorded and counted with the AniLab software.

Condition place aversion (CPA)

After habituation, mice were placed in the center of the two-chamber apparatus and allowed to explore either chamber for 15 minutes on Day 1. On Day 2, mice were restricted to one chamber (laser paired chamber) with photostimulation (473 nm, 20 Hz, 5 mW, 5 ms) for 30 minutes in the morning and restricted to the other chamber (unpaired chamber) without photostimulation in the afternoon. On Day 3, mice were restricted to the unpaired chamber without photostimulation in the morning and restricted to the laser paired chamber with photostimulation in the afternoon. On Day 4, mice were allowed to explore both chambers without laser stimulation for another 15 minutes. The time in the laser-paired chamber was calculated on Day 1 and Day 4.

2-MT-induced aversion

To assess the effect of optogenetic inhibition of the PBN-PVT projection or

PBN-PVT neurons on the aversive state, three cotton balls containing 15 mL 2-MT (1:1000) solution were placed in the black chamber. A constant laser (589 nm, 10 mW) was delivered during the 10 minutes test.

Cue-dependent optogenetic conditioning test

Video Freeze fear conditioning system with optogenetic equipment (MED Associates, MED-VFC-OPTO-USB-M) and Video Freeze software were used.

On Day 1, mice were habituated to the fear conditioning chambers and allowed to explore for 2 minutes freely, then three tones (75 dB, 4 kHz, 30 seconds duration) separated by a variable interval with a range of 60–120 seconds and the average of 90 seconds were delivered.

On Day 2, mice were trained with the sound cue (75 dB, 4 kHz, 30 seconds) paired with a simultaneous 30 seconds laser pulse train (20 Hz, 5 ms, 5 mW) for six times separated by a variable interval (averaging 90 seconds). The mice were kept in the conditioning chamber for another 60 seconds before returning to the home cages.

On Day 3, mice were placed back into the original training chamber for 3 minutes to perform the contextual test. After 2–3 hours, the conditioning chamber was modified by changing its metal floor and sidewalls. Mice were placed in the altered chamber for 3 minutes to measure the freezing level in the altered context. A tone (75 dB, 4 kHz) was delivered for 30 seconds to perform the cue test.

The behavior of the mice was recorded and analyzed with the Video Freeze software. Freezing was defined as the complete absence of movement for at least 0.5 seconds. On the conditioning day, the freezing percentages were calculated for 30 seconds during each tone/laser stimulus. For the contextual test, the freezing percentages were calculated for three minutes. For the cue test, the freezing percentages were calculated for 30 seconds during tone.

Auditory fear conditioning test

On Day one, mice were habituated to the fear conditioning chambers. On Day

two, mice were conditioned by seven trials of sound tone (75 dB, 4 kHz, 30 s) co-terminated with footshock (0.6 mA, 2 s) averagely separated by 90 seconds. Laser (589 nm, 10 mW) was delivered 1 second before the footshock and lasted for 4 seconds at each trial. On Day 3, mice were placed back into the original training chamber for 3 minutes to perform the contextual test, and the laser was delivered during the second minute. After 2–3 hours, the mice were placed into a modified chamber to perform the cue test. Three tones were given averagely separated by 90 seconds. The laser was delivered during the second tone.

The behavior of the mice was recorded and analyzed with the Video Freeze software. The freezing percentages of the 27 seconds tone before laser (to avoid the influence of laser) for each trial were summarized to indicate fear memory acquisition in the conditioning test. For the contextual test, the freezing percentages were calculated for every minute. For the cue test, the freezing percentages were calculated for 30 seconds during tone.

Freezing behavior

For analyses of freezing behavior induced by pharmacogenetic activation of PBN-PVT neurons, we injected CNO and recorded the mouse behavior using the Video Freeze fear conditioning system 30 minutes later.

The Video Freeze fear conditioning system (MED Associates, MED-VFC-OPTO-USB-M) was also used to assess the effect of optogenetic inhibition of PBN-PVT projection and the PBN-PVT neurons on the fear-like behavior induced by footshock. After free exploration of the chamber for 2 minutes, 15 times footshocks (0.6 mA, 1 second) were delivered within 10 minutes with a constant 589 nm laser (10 mW). The freezing percentages during 10 minutes were analyzed.

The Video Freeze fear conditioning system was also used to assess the effect of optogenetic inhibition of the PBN-PVT neurons on the fear-like behavior induced by 2-MT. 10 mL 2-MT (1:1000) dissolved in the ddH₂O was soaked into the cotton ball on the bottom of the training box. A constant laser

848 (589 nm, 10 mW) was delivered during the tests.

849 **Tail suspension test (TST)**

850 Mice were individually suspended by an adhesive tape placed roughly 2 cm
851 from the tip of the tail and videotaped for 6 minutes. Mice were considered
852 immobile without initiated movements, and the immobility time was scored in
853 the last 3 minutes by an observer unknown of the treatments.

854 **Forced swim test (FST)**

855 Mice were individually placed for 6 minutes in clear cylinders (45 cm height, 20
856 cm internal diameter) containing freshwater (25°C, 15 cm depth). The
857 swimming activity was videotaped, and immobility time in the last 3 minutes
858 was counted manually by an investigator unaware of animal grouping. The
859 mice were considered immobile when they stopped swimming/struggling or
860 only slightly moved to keep the nose above the surface.

861 **von Frey test**

862 The von Frey test was used to assess the mechanical sensitivity (*Mu et al.*,
863 2017). The mice were acclimated to the observation chambers for two days (2
864 hours for each day) before the test. A series of von Frey hairs with
865 logarithmically incrementing stiffness (0.16–2.0 grams) were used to stimulate
866 the mouse hind paw perpendicularly. The 50% paw withdrawal threshold was
867 determined using the up-down method.

868 **Hargreaves test**

869 Hargreaves tests were performed as described previously (*Mu et al.*, 2017).
870 Mice were placed in an individual plexiglass box with a glass floor. A radiant
871 heat beam was exposed directly to the hind paw until the paw was withdrawn.
872 The trials were repeated three times with an interval of at least 15 minutes. To
873 avoid potential damage, the test was executed with a 20 seconds cut-off time.

874 **Formalin test**

875 In the formalin test, the mice received an intraplantar injection of formalin (5%,
876 20 µl/mouse) and were placed into a plexiglass box (width: 10 cm, length: 10
877 cm, height: 15 cm) individually to record the pain-related licking behaviors for 1

hour. All videos were analyzed by trained investigators blinded to the experimental treatment of the animals.

Rotarod test

Mice were trained twice on a rotarod apparatus (MED Associates) with a rod accelerated 5–20 revolutions per minute (r.p.m.) for 5 minutes before the experimental day. On the second day, each mouse underwent three trials with a rod was programmed to accelerate from 0 to 40 r.p.m. over 300 seconds, then the average rpm at the point of falling was recorded.

Fiber photometry

In vivo fiber photometry experiments were performed as previously described (Zhu et al., 2020). After two weeks for virus expression, the mice were gently handled to be familiar with the calcium signal recording experiments (Thinker-Biotech). A signal (for synchronization) was manually tagged with the shock and air puff to evaluate the activity of PVT neurons. The calcium transient was recorded at 50 Hz. The fluorescence values change ($\Delta F/F$) was calculated from the formula of $(F-F_0)/F_0$ and the F_0 represented the median of the fluorescence values in the baseline period (–1 to –0.5 seconds relative to the stimulation onset). To precisely quantify the change of the fluorescence values across the shock or air-puff stimulation, we defined 0.5 to 1.0 seconds after the onset as the post-stimulus period.

Optoelectrode recording and analysis

The homemade optoelectrode consisted of an optic fiber (200 μ m in diameter) glued to 16 individually insulated nichrome wires (35 μ m internal diameter, 300–900 Kohm impedance, Stablohm 675, California Fine Wire). The 16 microwire arrays were arranged in a 4 + 4 + 4 + 4 pattern and soldered to an 18-pin connector (Mil-Max). Three weeks after virus injection, the optoelectrode was implanted to the PVT nucleus (AP –1.46 mm, ML 0 mm, DV –2.90 mm). After one week of recovery, two trials were performed continuously. Trial 1 contained ten sweeps of 2 s laser pulse trains (473 nm, 5 ms, 20 Hz, 8 mW). The interval of sweeps was 60 s. Trial 2 contained twenty sweeps of 2 s

footshock (0.5 mA). The interval of sweeps was 60 s. In the even time sweeps (2, 4, 6, 8, 10, 12, 14, 16, 18, 20), 2 s laser pulse trains were delivered spontaneously with the 2 s footshock. Neuronal signals were recorded using a Zeus system (Zeus, Bio-Signal Technologies: McKinney, TX, USA), and Spike signals were filtered online at 300 Hz. At the end of the experiment, all animals were perfused to confirm the optical fiber sites. Only the data of animals with correct optical fiber sites and virus expression regions were analyzed.

The spikes were sorted by the valley-seeking method with Offline Sorter software (Plexon, USA) and analyzed with NeuroExplorer (Nex Technologies: Boston, MA, U.S.A.). Firing rates of the neurons and timestamps were exported for further analysis using customized scripts in MATLAB. The Kolmogorov-Smirnov (K-S) test was used to compare the spike firing rate of PVT during 2 s baseline (before stimulus) and 2 s after each stimulus. $P < 0.001$ indicated statistical significance. The code generated during this study is available at: https://github.com/laizishangalali/Xiang/blob/main/zscore_KS_test.m (Xiang, 2021). Z-score normalization maps were constructed from normalized firing rates.

To calculate the latency of response of PVT neurons to laser and shock activation, we extracted the data in small bins of 2 ms. The onset of the response was calculated as the first of at least five consecutive bins higher than 20% above the baseline.

Quantification of the fiber intensity

For quantification of fluorescence of PVT_{PBN} efferents, the downstream targets of PVT_{PBN} neurons were taken photofluorograms with identical exposure time, the mean fluorescence value in each ROI (400 x 400 pixels) of each brain region was analyzed by Fiji. The fiber intensity was calculated as the fluorescence value of each brain region divided by that of the NAc. All data came from at least three different mice and were presented as mean $\pm$ SEM.

Analysis

Statistical detection methods include unpaired student's *t*-test, paired student's *t*-test, one-way ANOVA with Bonferroni's correction for multiple comparisons, two-way ANOVA with Bonferroni's correction for multiple comparisons. A value of $p < 0.05$ was considered statistically significant. All data were represented as mean $\pm$ SEM.

Data availability statement

All data generated or analysed during this study are included in the manuscript and supporting file. The behavioral data and imaging analysis results have been made available on Dryad Digital Repository (<https://doi:10.5061/dryad.1rn8pk0w4>). All MATLAB code has been deposited at: https://github.com/laizishangalali/Xiang/blob/main/zscore_KS_test.m and is publicly available.

REFERENCES

- Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. 2007. Evolving the lock to fit the key to create a family of G protein-coupled receptors potentially activated by an inert ligand. *PNAS*, **104**:5163-5168. DOI: <https://doi.org/10.1073/pnas.0700293104>, PMID:17360345
- Barson JR, Mack NR, Gao WJ. The paraventricular nucleus of the thalamus is an important node in the emotional processing network. 2020. *Front Behav Neurosci*, **14**:598469. DOI: 10.3389/fnbeh.2020.598469. PMID: 33192373
- Beas BS, Wright BJ, Skirzewski M, Leng Y, Hyun JH, Koita O, Ringelberg N, Kwon HB, Buonanno A, Penzo MA. 2018. The locus coeruleus drives disinhibition in the midline thalamus via a dopaminergic mechanism. *Nature Neuroscience*, **21**:963-973. DOI: <https://doi.org/10.1038/s41593-018-0167-4>, PMID:29915192
- Bowen AJ, Chen JY, Huang YW, Baertsch NA, Park S, Palmiter RD. 2020. Dissociable control of unconditioned responses and associative fear learning by parabrachial CGRP neurons. *eLife*, **9**. DOI:

968 <https://doi.org/10.7554/eLife.59799>, PMID:32856589

969 Cai YQ, Wang W, Paulucci-Holthauzen A, Pan ZZ. 2018. Brain circuits
 970 mediating opposing effects on emotion and pain. *Journal of Neuroscience*,
 971 **38**:6340-6349. DOI: <https://doi.org/10.1523/JNEUROSCI.2780-17.2018>,
 972 PMID:29941444

973 Campos CA, Bowen AJ, Roman CW, Palmiter RD. 2018. Encoding of danger
 974 by parabrachial CGRP neurons. *Nature*, **555**:617-622. DOI:
 975 <https://doi.org/10.1038/nature25511>, PMID:29562230

976 Chen M, Bi LL. 2019. Optogenetic long-term depression induction in the
 977 PVT-CeL circuitry mediates decreased fear memory. *Mol Neurobiol*,
 978 **56**:4855-4865. DOI: 10.1007/s12035-018-1407-z. PMID: 30406427

979 Chiang MC, Bowen A, Schier LA, Tupone D, Uddin O, Heinricher MM. 2019.
 980 Parabrachial complex: a hub for pain and aversion. *Journal of Neuroscience*,
 981 **39**:8225-8230. DOI: <https://doi.org/10.1523/JNEUROSCI.1162-19.2019>,
 982 PMID:31619491

983 Chiang MC, Nguyen EK, Canto-Bustos M, Papale AE, Oswald AM, Ross SE.
 984 2020. Divergent neural pathways emanating from the lateral parabrachial
 985 nucleus mediate distinct components of the pain response. *Neuron*,
 986 **106**:927-939. DOI: <https://doi.org/10.1016/j.neuron.2020.03.014>,
 987 PMID:32289251

988 Deng J, Zhou H, Lin JK, Wei YC, Xu XH, Sun YG. 2020. The parabrachial
 989 nucleus directly channels spinal nociceptive signals to the intralaminar
 990 thalamic nuclei, but not the amygdala. *Neuron*, **107**:909-923. DOI:
 991 <https://doi.org/10.1016/j.neuron.2020.06.017>, PMID:32649865

992 Dimitrov EL, Tsuda MC, Cameron HA, Usdin TB. 2014. Anxiety- and
 993 depression-like behavior and impaired neurogenesis evoked by peripheral
 994 neuropathy persist following resolution of prolonged tactile hypersensitivity.
 995 *Journal of neuroscience*, **34**:12304-12312. DOI:
 996 <https://doi.org/10.1523/JNEUROSCI.0312-14.2014>, PMID:25209272

997 Do-Monte FH, Minier-Toribio A, Quiñones-Laracuente K, Medina-Colón EM,

998 Quirk GJ. 2017. Thalamic regulation of sucrose seeking during unexpected
 999 reward omission. *Neuron*, **94**:388-400. DOI: 10.1016/j.neuron.2017.03.036,
 1000 PMID:28426970

1001 Do-Monte FH, Quinones-Laracuente K, Quirk GJ. 2015. A temporal shift in the
 1002 circuits mediating retrieval of fear memory. *Nature*, **519**:460-463. DOI:
 1003 <https://doi.org/10.1038/nature14030>, PMID:25600268

1004 Engelke DS, Zhang XO, O'Malley JJ, Fernandez-Leon JA, Li S, Kirouac GJ,
 1005 Beierlein M, Do-Monte FH. 2021. A hypothalamic-thalamostriatal circuit that
 1006 controls approach-avoidance conflict in rats. *Nat Commun*, 12:2517. DOI:
 1007 10.1038/s41467-021-22730-y. PMID: 33947849

1008 Gao C, Leng Y, Ma J, Rooke V, Rodriguez-Gonzalez S, Ramakrishnan C,
 1009 Deisseroth K, Penzo MA. 2020. Two genetically, anatomically and
 1010 functionally distinct cell types segregate across anteroposterior axis of
 1011 paraventricular thalamus. *Nat Neurosci*, **23**:217-228. DOI:
 1012 10.1038/s41593-019-0572-3. PMID: 31932767

1013 Han S, Soleiman MT, Soden ME, Zweifel LS, Palmiter RD. 2015. Elucidating
 1014 an affective pain circuit that creates a threat memory. *Cell*, **162**:363-374. DOI:
 1015 <https://doi.org/10.1016/j.cell.2015.05.057>, PMID:26186190

1016 Hsu DT, Kirouac GJ, Zubieta JK, Bhatnagar S. 2014. Contributions of the
 1017 paraventricular thalamic nucleus in the regulation of stress, motivation, and
 1018 mood. *Frontiers in Behavioral Neuroscience*, **8**:73. DOI:
 1019 <https://doi.org/10.3389/fnbeh.2014.00073>, PMID:24653686

1020 Huang TW, Lin SH, Malewicz NM, Zhang Y, Zhang Y, Goulding M, LaMotte RH,
 1021 Ma QF. 2019. Identifying the pathways required for coping behaviours
 1022 associated with sustained pain. *Nature*, **565**:86-90. DOI:
 1023 <https://doi.org/10.1038/s41586-018-0793-8>, PMID:30532001

1024 Isosaka T, Matsuo T, Yamaguchi T, Funabiki K, Nakanishi S, Kobayakawa R,
 1025 Kobayakawa K. 2015. Htr2a-expressing cells in the central amygdala control
 1026 the hierarchy between innate and learned fear. *Cell*, **163**:1153-1164. DOI:
 1027 <https://doi.org/10.1016/j.cell.2015.10.047>, PMID:26590419

1028 Jennings JH, Sparta DR, Stamatakis AM, Ung RL, Pleil KE, Kash TL, Stuber
 1029 GD. 2013. Distinct extended amygdala circuits for divergent motivational
 1030 states. *Nature*, **496**:224-228. DOI: <https://doi.org/10.1038/nature12041>,
 1031 PMID:23515155
 1032 Jimenez JC, Su K, Goldberg AR, Luna VM, Biane JS, Ordek G, Zhou P, Ong
 1033 SK, Wright MA, Zweifel L, Paninski L, Hen R, Kheirbek MA. 2018. Anxiety
 1034 cells in a hippocampal-hypothalamic circuit. *Neuron*, **97**:670-683. DOI:
 1035 <https://doi.org/10.1016/j.neuron.2018.01.016>, PMID:29397273
 1036 Kaur S, Pedersen NP, Yokota S, Hur EE, Fuller PM, Lazarus M, Chamberlin
 1037 NL, Saper CB. 2013. Glutamatergic Signaling from the Parabrachial Nucleus
 1038 Plays a Critical Role in Hypercapnic Arousal. *Journal of Neuroscience*,
 1039 **33**:7627-7640. DOI: <https://doi.org/10.1523/Jneurosci.0173-13.2013>,
 1040 PMID:WOS:000318420400003
 1041 Keyes PC, Adams EL, Chen Z, Bi L, Nachtrab G, Wang VJ, Tessier-Lavigne M,
 1042 Zhu Y, Chen X. 2020. Orchestrating opiate-associated memories in thalamic
 1043 circuits. *Neuron*, **107**:1113-1123.e4. DOI: [10.1016/j.neuron.2020.06.028](https://doi.org/10.1016/j.neuron.2020.06.028).
 1044 PMID: 32679036
 1045 Li S, Kirouac GJ. 2008. Projections from the paraventricular nucleus of the
 1046 thalamus to the forebrain, with special emphasis on the extended amygdala.
 1047 *J Comp Neurol*, **506**:263-87. DOI:10.1002/cne.21502. PMID: 18022956
 1048 Li S, Kirouac GJ. 2012. Sources of inputs to the anterior and posterior aspects
 1049 of the paraventricular nucleus of the thalamus. *Brain Structure & Function*,
 1050 **217**:257-273. DOI: <https://doi.org/10.1007/s00429-011-0360-7>,
 1051 PMID:22086160
 1052 Liang SH, Yin JB, Sun Y, Bai Y, Zhou KX, Zhao WJ, Wang W, Dong YL, Li YQ.
 1053 2016. Collateral projections from the lateral parabrachial nucleus to the
 1054 paraventricular thalamic nucleus and the central amygdaloid nucleus in the
 1055 rat. *Neuroscience Letters*, **629**:245-250. DOI:
 1056 <https://doi.org/10.1016/j.neulet.2016.07.017>, PMID:27423318
 1057 Liang SH, Zhao WJ, Yin JB, Chen YB, Li JN, Feng B, Lu YC, Wang J, Dong YL,

Li YQ. 2020. A neural circuit from thalamic paraventricular nucleus to central amygdala for the facilitation of neuropathic pain. *Journal of Neuroscience*, **40**:7837-7854. DOI: <https://doi.org/10.1523/JNEUROSCI.2487-19.2020>, PMID:32958568

Mu D, Deng J, Liu KF, Wu ZY, Shi YF, Guo WM, Mao QQ, Liu XJ, Li H, Sun YG. 2017. A central neural circuit for itch sensation. *Science*, **357**:695-699. DOI: <https://doi.org/10.1126/science.aaf4918>, PMID:28818946

Nakahara TS, Carvalho VMA, Souza MAA, Trintinalia GZ, Papes F. 2020. Detection of activated mouse neurons with temporal resolution via dual c-Fos staining. *STAR Protoc*, **1**:100153. DOI: 10.1016/j.xpro.2020.100153. PMID: 33377047

Öhman A, Mineka S. 2001. Fears, phobias, and preparedness: Toward an evolved module of fear and fear learning. *Psychological Review*, **108**:483-522. DOI: <https://doi.org/10.1037/0033-295x.108.3.483>, PMID:11488376

Palmiter RD. 2018. The parabrachial nucleus: CGRP neurons function as a general alarm. *Trends in Neurosciences*, **41**:280-293. DOI: <https://doi.org/10.1016/j.tins.2018.03.007>, PMID:29703377

Penzo MA, Robert V, Tucciarone J, De Bundel D, Wang M, Van Aelst L, Darvas M, Parada LF, Palmiter RD, He M, Huang ZJ, Li B. 2015. The paraventricular thalamus controls a central amygdala fear circuit. *Nature*, **519**:455-459. DOI: <https://doi.org/10.1038/nature13978>, PMID:25600269

Ren SC, Wang YL, Yue FG, Cheng XF, Dang RZ, Qiao QC, Sun XQ, Li X, Jiang Q, Yao JW, Qin H, Wang GZ, Liao X, Gao D, Xia JX, Zhang J, Hu B, Yan JA, Wang YJ, Xu M, et al. 2018. The paraventricular thalamus is a critical thalamic area for wakefulness. *Science*, **362**:429-434. DOI: <https://doi.org/10.1126/science.aat2512>, PMID:30361367

Saper CB. 2016. The house alarm. *Cell Metabolism*, **23**:754-755. DOI: <https://doi.org/10.1016/j.cmet.2016.04.021>, PMID:27166934

Sun L, Liu R, Guo F, Wen MQ, Ma XL, Li KY, Sun H, Xu CL, Li YY, Wu MY, Zhu ZG, Li XJ, Yu YQ, Chen Z, Li XY, Duan SM. 2020. Parabrachial nucleus

circuit governs neuropathic pain-like behavior. *Nature Communications*, **11**.
 DOI: <https://doi.org/10.1038/s41467-020-19767-w>, PMID:33239627

Todd AJ. 2010. Neuronal circuitry for pain processing in the dorsal horn. *Nature Review Neuroscience*, **11**:823-836. DOI: <https://doi.org/10.1038/nrn2947>, PMID:21068766

Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H, Thompson KR, Gradinaru V, Ramakrishnan C, Deisseroth K. 2011. Amygdala circuitry mediating reversible and bidirectional control of anxiety. *Nature*, **471**:358-362. DOI: <https://doi.org/10.1038/nature09820>, PMID:21389985

Vertes RP, Linley SB, Hoover WB. 2015. Limbic circuitry of the midline thalamus. *Neuroscience and Biobehavioral Review*, **54**:89-107. DOI: <https://doi.org/10.1016/j.neubiorev.2015.01.014>, PMID:25616182

Xiang AF. 2021. Xiang. Github. https://github.com/laizishangalali/Xiang/blob/main/zscore_KS_test.m. ce467c6

Yamamuro K, Bicks LK, Leventhal MB, Kato D, Im S, Flanigan ME, Garkun Y, Norman KJ, Caro K, Sadahiro M, Kullander K, Akbarian S, Russo SJ, Morishita H. 2020. A prefrontal-paraventricular thalamus circuit requires juvenile social experience to regulate adult sociability in mice. *Nature Neuroscience*, **23**:1240-1252. DOI: <https://doi.org/10.1038/s41593-020-0695-6>, PMID:32868932

Zhou WJ, Jin Y, Meng Q, Zhu X, Bai TJ, Tian YH, Mao Y, Wang LK, Xie W, Zhong N, Luo M, H., Tao WJ, Wang HT, Li J, Qiu BS, Zhou JN, Li XY, Xu H, Wang K, Zhang XC, et al. 2019. A neural circuit for comorbid depressive symptoms in chronic pain. *Nature Neuroscience*, **22**:1649-1658. DOI: <https://doi.org/10.1038/s41593-019-0468-2>, PMID:31451801

Zhu YJ, Nachtrab G, Keyes PC, Allen WE, Luo LQ, Chen XK. 2018. Dynamic salience processing in paraventricular thalamus gates associative learning. *Science*, **362**:423-429. DOI: <https://doi.org/10.1126/science.aat0481>, PMID:30361366

Zhu Y, Wienecke CF, Nachtrab G, Chen X. 2016. A thalamic input to the nucleus accumbens mediates opiate dependence. *Nature*, **530**:219-222. DOI: <https://doi.org/10.1038/nature16954>, PMID:26840481

Zhu YB, Xu L, Wang Y, Zhang Rui, Wang YC, Li JB, Mu D. 2020. Posterior thalamic nucleus mediates facial histaminergic itch. *Neuroscience*, **444**:54-63. DOI: <https://doi.org/10.1016/j.neuroscience.2020.07.048>, PMID:32750381

Zingg B, Chou XL, Zhang ZG, Mesik L, Liang F, Tao HW, Zhang LI. 2017. AAV-Mediated anterograde transsynaptic tagging: mapping corticocollicular input-defined neural pathways for defense behaviors. *Neuron*, **93**:33-47. DOI: <https://doi.org/10.1016/j.neuron.2016.11.045>, PMID:27989459

Figures and figure legends

Figure 1. Functional connectivity pattern of PBN-PVT projections. (A) The schematic for virus injection of AAV2/8-hSyn-ChR2-mCherry into the PBN nucleus and the slice recording with 473 nm laser stimulation. (B) The projection fibers in the PVT nucleus. Scale bar: 100 μ m. (C) The

AAV2/8-hSyn-ChR2-mCherry virus expression in the PBN nucleus. Scale bar: 200 μ m. (D–F) The locations of the recorded cells in the anterior PVT (D), the middle PVT (E), and the posterior PVT (F). Red circles indicated neurons with excitatory postsynaptic currents (EPSCs), and blue circles indicated neurons without EPSCs. (G) The 473 nm laser-induced time-locked action potential firing at 5 Hz (top), 10 Hz (middle), and 20 Hz (bottom) in the ChR2-expressing neuron in the PBN. Scale bars: 100 ms, 40 mV. (H–J) The amplitude of light-evoked EPSCs (H), the latency of EPSCs (I), and the latency jitter of EPSCs (J) from all 34 responsive neurons in the PVT. (K) Amplitudes of light-evoked EPSCs recorded from a PVT neuron (right panel). (L) The light-evoked EPSC was completely blocked by 1 μ M tetrodotoxin (TTX), rescued by 100 μ M 4-aminopyridine (4-AP), and blocked by 10 μ M NBQX (AMPA/kainate receptor antagonist). Scale bars: 5 ms, 10 pA. (M) Schematic shows retroAAV2/2-hSyn-Cre injection into the PVT nucleus on *Rosa26-tdTomato* mice. (N) The injection site in the PVT nucleus. Scale bar: 200 μ m. (O and P) The distribution of the tdTomato positive neurons in the left PBN (O) and the right PBN (P). (Q) The quantification of the tdTomato positive neurons in the lateral PBN (LPBN) and the media PBN (MPBN). $n = 4$ mice. Scale bar: 200 μ m. (R–T) Double staining of tdTomato with *Slc17a6* mRNA by in situ hybridization. Scale bar: 50 μ m, the scale bar in the quadrangle was 25 μ m. (U) Quantification of the double-positive neurons over the total number of tdTomato positive neurons, $n = 6$ sections from 3 mice. *** $p < 0.001$, data were represented as mean $\pm$ SEM. Paired student's *t*-test for Q.

The following figure supplement is available for figure 1:

Figure 1–figure supplement 1. Characterization of PBN-PVT neurons.

Figure 1–figure supplement 2. The distribution pattern of PBN-PVT glutamatergic projection.

Figure 1–figure supplement 3. The distribution pattern of collateral projection fibers from PBN-PVT neurons.

1166

1167 **Figure 2.** Optogenetic activation of PBN-PVT projections induced negative
 1168 affective states. (A) The illustration showed the injection of
 1169 AAV2/9-EF1 α -DIO-ChR2-mCherry virus into the PBN nucleus and the optic
 1170 fiber above the PVT on the Vglut2-ires-Cre mice. (B and C) The virus injection
 1171 sites of the left PBN (B) and the right PBN (C). Scale bar: 200 μ m. (D) The
 1172 projection axons from the PBN and the location of the optic fiber (rectangle) in
 1173 the PVT. Scale bar: 200 μ m. (E) The schematic of the open field test (OFT)
 1174 with optogenetic activation via a 473 nm laser (20 Hz, 5 mW, 5 ms). (F and G)
 1175 The example traces of the 15 minutes optogenetic manipulation OFT from an

AAV2/9-EF1 α -DIO-mCherry virus-injected mouse (F) or an AAV2/9-EF1 α -DIO-ChR2-mCherry virus-injected mouse (G). (H and I) Quantification of the velocity (H) and the center time (I) in the OFT, mCherry group: $n = 7$ mice; ChR2 group: $n = 8$ mice. (J) The illustration of the real-time place aversion test (RTPA) with optogenetic activation via a 473 nm laser. The right side was paired with the laser. (K and L) The example traces of the RTPA and post-test from the mice injected with AAV2/9-EF1 α -DIO-mCherry (K) or AAV2/9-EF1 α -DIO-ChR2-mCherry (L). (M) Quantification of the time spent in the laser-paired chamber in the pre-test (Pre), RTPA, and post-test (Post), mCherry group: $n = 7$ mice; ChR2 group: $n = 8$ mice. (N) Schematic timeline of cue-dependent optogenetic conditioning. (O) Conditioned-freezing responses to sound cue paired with optogenetic activation of the PBN-PVT projection during training, mCherry group: $n = 4$ mice; ChR2 group: $n = 5$ mice. (P and Q) Optogenetic activation of the projection fibers from the PBN in the PVT did not induce context-dependent fear (P) and cue-dependent fear (Q), mCherry group: $n = 4$ mice; ChR2 group: $n = 5$ mice. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, all data were represented as mean $\pm$ SEM. Two-way ANOVA followed by Bonferroni test for H, I, M, and O. Unpaired student's t -test for P and Q.

The following figure supplement is available for figure 2:

Figure 2-figure supplement 1. Virus expression in the PBN and the optic fiber position in the PVT of Vglut2-ires-Cre mice injected with AAV2/9-EF1 α -DIO-ChR2-mCherry virus or AAV2/9-EF1 α -DIO-mCherry virus.

Figure 2-figure supplement 2. Effects of optogenetic activation of PBN-PVT projections in the OFT and the CPA.

Figure 2-video 1. Optogenetic activation of PBN-PVT projections in OFT. The 473 nm laser (20 Hz, 5 mW, 5 ms) was delivered from 00:10 to 05:10 in the video.

Figure 2-video 2. Optogenetic activation of PBN-PVT projections in RTPA. The 473 nm laser (20 Hz, 5 mW, 5 ms) was delivered when the mouse entered

the laser-paired chamber and withdrew when the mouse exited the laser-paired chamber during the 10 minutes. The video was played with 4x speed.

Figure 3. Pharmacogenetic activation of PBN-PVT neurons induced anxiety-like behaviors and fear-like behaviors. Pharmacogenetic activation of the PBN-PVT neurons induced anxiety-like behaviors and fear-like behaviors. (A) The illustration showed virus injection of retroAAV2/2-hSyn-Cre into the PVT nucleus and bilateral injection of AAV2/9-hSyn-DIO-hM3Dq-mCherry into the PBN nucleus. (B and C) CNO administration evokes Fos expression in AAV2/9-hSyn-DIO-hM3Dq-mCherry injected mice (B) but not in AAV2/9-EF1 α -DIO-mCherry injected mice (C). Scale bar: 200 μ m. (D) Percentage of co-labeled neurons in the PBN, mCherry group: $n = 3$ mice; hM3Dq group: $n = 4$ mice. (E) The illustration of the OFT test with pharmacogenetic activation. (F) Example of the OFT traces from the mice infected with AAV2/9-EF1 α -DIO-mCherry or AAV2/9-hSyn-DIO-hM3Dq-mCherry. (G–I) Quantification of the center time (G),

the immobility time (H), the total distance (I) in the OFT, mCherry group: $n = 7$ mice; hM3Dq group: $n = 8$ mice. (J) Quantification of the velocity in the OFT, mCherry group: $n = 7$ mice; hM3Dq group: $n = 5$ mice. (K) Example elevated zero maze (EZM) traces from the mice infected with AAV2/9-EF1 α -DIO-mCherry and AAV2/9-hSyn-DIO-hM3Dq-mCherry. (L) Quantification of the time spent in open quadrants in the EZM test, $n = 8$ mice per group. (M) The illustration of pharmacogenetic activation-induced fear-like freezing behavior. (N) Pharmacogenetic activation of PBN-PVT neurons induced fear-like freezing behaviors, mCherry group: $n = 8$ mice; hM3Dq group: $n = 7$ mice. * $p < 0.05$, *** $p < 0.001$, all data were represented as mean $\pm$ SEM. Unpaired student's t -test for D, G, H, I, and J. Two-way ANOVA followed by Bonferroni test for L and N.

The following figure supplements are available for figure 3:

Figure 3–figure supplement 1. Virus expression in the PBN of mice injected with AAV2/9-hSyn-DIO-hM3Dq-mCherry or AAV2/9-EF1 α -DIO-mCherry in the pharmacogenetic manipulation.

Figure 3–figure supplement 2. Pharmacogenetic activation of PBN-PVT neurons did not affect depressive-like behaviors, basal nociceptive thresholds, formalin-induced licking behavior, or motor function.

Figure 4. Optogenetic inhibition of PBN-PVT projections reduced aversion-like behavior and fear-like behaviors. (A) The illustration showed the bilateral injection of AAV2/9-EF1 α -DIO-NpHR3.0-EYFP virus into the PBN and placement of optic fiber above the PVT on Vglut2-ires-Cre mice. (B and C) Examples of AAV2/9-EF1 α -DIO-NpHR3.0-EYFP expression in the PVT (B) and PBN (C). The cyan rectangle represented the position of the optic fiber. Scale bar: 200 μ m. (D) Schematic of 2-MT induced aversion test with optogenetic inhibition via the 589 nm laser. (E) Representative traces of the mice infected with AAV2/8-EF1 α -DIO-EGFP or AAV2/9-EF1 α -DIO-NpHR3.0-EYFP in two chambers. (F and G) Quantification of the time spent in the 2-MT paired chamber (F) and the total moving duration (G), $n = 7$ mice per group. * $p < 0.05$, ** $p < 0.01$, (H) Representative traces of the mice infected with AAV2/8-EF1 α -DIO-EGFP or AAV2/9-EF1 α -DIO-NpHR3.0-EYFP in the OFT chamber. (I) Quantification of the time spent in the 2-MT zone, $n = 7$ mice per group. (J) Illustration of footshock-induced freezing behavior with optogenetic inhibition via a 589 nm

laser. (K) Quantification of the freezing behavior, $n = 7$ mice per group. $*p < 0.05$, all data were represented as mean $\pm$ SEM. Unpaired student's t -test for F, G, I, and K.

The following figure supplements are available for figure 4:

Figure 4-figure supplement 1. Virus expression in the PBN and the optic fiber position in the PVT of Vglut2-ires-Cre mice injected with AAV2/9-EF1 α -DIO-NpHR3.0-EYFP or AAV2/8-EF1 α -DIO-EGFP.

Figure 4-figure supplement 2. Optogenetic inhibition of the PBN-PVT projections did not affect associative fear memory acquisition and retrieval.

Figure 4-figure supplement 3. Optogenetic inhibition of the PBN-PVT neurons reduced the aversion-like behavior and fear-like freezing behavior.

Figure 5. Activation of PVT_{PBN} neurons by diverse aversive stimuli. (A) The illustration showed the injection of AAV2/1-hSyn-Cre into the PBN of *Rosa26-tdTomato* mice. (B–D) The distribution of the neurons in the PVT at bregma -1.06 mm (B), bregma -1.46 mm (C), and bregma -1.70 mm (D). Scale bar: 200 μ m. (E–G) Fos induced by habituation control (E), footshock (F), or 2-MT (G) co-labeled with the tdTomato positive neurons in the PVT. Scale bar: 200 μ m. (H) Quantification of the co-labeled neurons, $n = 3$ mice per group. $*p$

< 0.05, **p < 0.01, ***p < 0.001, all data were represented as mean ± SEM, one-way ANOVA followed by Bonferroni test for H.

The following figure supplements are available for figure 5:

Figure 5–figure supplement 1. Calcium signals of PVT neurons in response to aversive stimuli.

Figure 6. Neuronal activity of PVT neurons in response to the footshock was modulated by PBN-PVT projections. (A) Top: Schematic showed injection of AAV2/9-EF1α-DIO-ChR2-mCherry into the PBN and placement of the optoelectrode above the PVT of Vglut2-ires-Cre mice. Bottom: The protocol of 10 sweeps of laser stimuli (Trial 1) and 20 sweeps of footshock stimuli without or with laser (Trial 2). (B) Firing rates (z-score) of 40 neurons during laser stimuli (20 Hz, 5 mW, 5 ms, 2 s). Inserted: percentages of different groups of neurons according to z-score. (C) Firing rates (z-score) of 40 neurons during footshock (0.5 mA, 2 s) without laser stimuli. (D) Percentage of laser-activated, footshock-activated, and both stimuli-activated neurons. (E-G) Rastergrams and firing rates showed the spiking activity of one PVT neuron during laser stimulus (E), footshock without laser stimulus (F), and footshock with laser stimulus (G). (H) Firing rates (z-score) of 40 neurons during footshock (0.5 mA, 2 s) with laser stimuli (20 Hz, 5 mW, 5 ms, 2 s). (I) Quantification of the firing

rates of 40 neurons before and during footshock without and with laser, $n = 40$ neurons. $**p < 0.01$, $***p < 0.001$, all data were represented as mean $\pm$ SEM, two-way ANOVA followed by Bonferroni test for I.

The following figure supplements are available for figure 6:

Figure 6–figure supplement 1. Dual Fos staining detecting Fos protein and *fos* mRNA induced by laser stimulation and footshock.

Figure 6–figure supplement 2. The response latency of PVT neurons to laser activation and footshock activation.

Figure 7. Activation of PVT_{PBN} neurons induced anxiety-like behaviors. (A) The illustration showed injection of AAV2/1-hSyn-Cre into the PBN and AAV2/9-hSyn-DIO-hM3Dq-mCherry into the PVT. (B and C) CNO administration evoked Fos expression in AAV2/9-hSyn-DIO-hM3Dq-mCherry injected mice (B) but not in AAV2/9-EF1 α -DIO-mCherry injected mice (C). Scale bar: 200 μ m. (D) Percentage of co-labeled neurons in the PVT, $n = 4$ mice per group. (E) The illustration of the OFT test with pharmacogenetic activation. (F) Quantification of center time in the OFT, $n = 7$ mice per group. (G) Example of elevated zero maze (EZM) traces from the mice injected with AAV2/9-EF1 α -DIO-mCherry or AAV2/9-hSyn-DIO-hM3Dq-mCherry. (H and I) Quantification of the time spent in open quadrants (H) and the immobility time in the EZM test (I), $n = 7$ mice per group. $*p < 0.05$, $***p < 0.001$, all data were

presented as mean $\pm$ SEM. Unpaired student's *t*-test for D, F, H, and I.

The following figure supplements are available for figure 7:

Figure 7-figure supplement 1. Distribution pattern of projection fibers of PVT_{PBN} neurons.

Figure 1-figure supplement 1. Characterization of PBN-PVT neurons. (A-O) Double staining of tdTomato signals (red) with *Tacr1* mRNA (A-C), *Tac1* mRNA (E-G), *Pdyn* mRNA (I-K), and CGRP protein (M-O). Scale bar: 100 μ m. (D, H and L) The proportions of co-expressing neurons of tdTomato positive neurons, *n* = 6 sections from 3 mice. *Tacr1*, tachykinin 1 receptor;

Tac1, tachykinin 1; Pdyn, prodynorphin; CGRP, calcitonin gene-related peptide.

Figure 1-figure supplement 2. The distribution pattern of the PBN-PVT glutamatergic projection. (A) The illustration for virus injection of AAV2/8-EF1 α -DIO-EGFP into the PBN nucleus on Vglut2-ires-Cre mice. (B–D) The virus expression in the anterior (B), the middle (C), and the posterior PBN (D). Scale bar: 200 μ m. (E–H) The distribution pattern of PBN glutamatergic projection fibers in the anterior (E and F), the middle (G), and the posterior PVT (H). PVA, anterior paraventricular thalamus. Scale bar: 200 μ m.

Figure 1-figure supplement 3. The distribution pattern of collateral projection fibers from PBN-PVT neurons. (A) The illustration showed the injection of retroAAV2/2-hSyn-Cre into the PVT and AAV2/8-EF1 α -DIO-EGFP into the PBN to label the PBN-PVT neurons. (B) Examples of AAV2/8-EF1 α -DIO-EGFP expression in the PBN. Scale bar: 200 μ m. (C–N) The efferents from the PBN-PVT neurons could be found in the MnPo (C), BNST (D), LH (E), PVN (F), PVT (G), ILN (H), DM (I), PSTh (J), VTA (K) and PAG (L) but not in the CeA (M) and VMH (N). (O) Schematic showing summary of the distribution pattern of fibers from PBN-PVT neurons. MnPo, Median preoptic nucleus; BNST, bed nucleus of the stria terminalis; LH, lateral hypothalamic area; PVN, paraventricular nucleus of the hypothalamus; ILN, intralaminar thalamic nucleus; DM, dorsomedial hypothalamic nucleus; PSTh,

parasubthalamic nucleus; VTA, ventral tegmental areas; PAG, periaqueductal gray; CeA, central nucleus of the amygdala; VMH, ventromedial hypothalamic nucleus.

Figure 2-figure supplement 1. Virus expression in the PBN and the optic fiber position in the PVT of Vglut2-ires-Cre mice injected with AAV2/9-EF1 α -DIO-ChR2-mCherry virus or AAV2/9-EF1 α -DIO-mCherry virus. (A) Histological map showing area of ChR2 expression in the PBN at bregma -5.20 mm in 8 mice. Scale bar: 400 μ m. (B) The position of optic fiber (rectangle) in the PVT in the AAV2/9-EF1 α -DIO-ChR2-mCherry injected mice. Scale bar: 200 μ m. (C) The area of AAV2/9-EF1 α -DIO-mCherry virus expression in the PBN at bregma -5.20 mm in 7 mice. Scale bar: 400 μ m. (D)

Position of the optic fiber tip from 7 mice injected with AAV2/9-EF1 α -DIO-mCherry. Scale bar: 200 μ m.

Figure 2-figure supplement 2. Effects of optogenetic activation of PBN-PVT projections in the OFT and the CPA. (A and B) Quantification of the immobility time (A) and the distance (B) in the OFT (mCherry group: $n = 7$ mice; ChR2 group: $n = 8$ mice). (C–F) Quantification of the velocity (C), the immobility time (D), the center time (E), the distance (F), and the number of jumps (G) during the 5–10 minutes laser ON period in the OFT test (mCherry group: $n = 7$ mice; ChR2 group: $n = 8$ mice). (H) Protocol for the prolonged conditioned place aversion (CPA). (I) Photostimulation of PBN-PVT projection did not induce CPA ($n = 7$ mice per group). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, all data were represented as mean $\pm$ SEM. Two-way ANOVA followed by Bonferroni test for A, B, and I. Two-way ANOVA with interaction factors for C, D, E, F, G,

Figure 3-figure supplement 1. Virus expression in the PBN of mice injected with AAV2/9-hSyn-DIO-hM3Dq-mCherry or AAV2/9-EF1 α -DIO-mCherry in the pharmacogenetic manipulation experiment. (A) Representative histological images of hM3Dq expression in an AAV2/9-hSyn-DIO-hM3Dq-mCherry injected mouse at brain level from bregma -5.02 mm to bregma -5.34 mm. Scale bar: 1 mm. (B) Depiction of virus infection area according to the

histological images in (A). (C) Superimposed depiction of virus transduction from 8 mice. (D) Representative histological images of mCherry expression in an AAV2/9-EF1 α -DIO-mCherry injected mice at brain level from bregma -5.02 mm to bregma -5.34 mm. Scale bar: 1 mm. (E) Depiction of virus infection area according to the histological images in (D). (F) Superimposed depiction of virus transduction from 8 mice.

Figure 3-figure supplement 2. Pharmacogenetic activation of PBN-PVT neurons did not affect depressive-like behaviors, basal nociceptive thresholds, formalin-induced licking behavior, or motor function. (A) Immobility time in the tail suspension test (TST), $n = 7$ mice per group. (B) Immobility time in the forced swimming test (FST), mCherry group: $n = 7$ mice; hM3Dq group: $n = 8$ mice. (C and D) Effects of pharmacogenetic activation of PBN-PVT neurons on the nociceptive response tested by von Frey (C) and Hargreaves (D), $n = 8$ mice per group. (E and F) Duration of licking behaviors in the formalin-induced inflammatory pain test, mCherry group: $n = 7$ mice; hM3Dq group: $n = 8$ mice. Phase I: 0–10 minutes, Phase II: 10–60 minutes. (G) The latency to fall in the rotarod test, $n = 8$ mice per group. Data were represented as mean $\pm$ SEM. Unpaired student's t -test for A, B and G. Two-way ANOVA followed by Bonferroni test for C, D, E, and F.

Figure 4-figure supplement 1. Virus expression in the PBN and the optic fiber position in the PVT of Vglut2-ires-Cre mice injected with AAV2/9-EF1 α -DIO-NpHR3.0-EYFP or AAV2/8-EF1 α -DIO-EGFP. (A) Histological map showing area of NpHR3.0 expression in the PBN at bregma -5.20 mm in 7 mice. Scale bar: 400 μ m. (B) The position of optic fiber (rectangle) in the PVT in the AAV2/9-EF1 α -DIO-NpHR3.0-EYFP injected mice. Scale bar: 200 μ m. (C) The area of AAV2/8-EF1 α -DIO-EGFP expression in the PBN at bregma -5.20 mm in 7 mice. Scale bar: 400 μ m. (D) Position of the optic fiber tip from 7 mice injected with AAV2/9-EF1 α -DIO-mCherry. Scale bar: 200 μ m.

Figure 4-figure supplement 2. Optogenetic inhibition of PBN-PVT projections did not affect associative fear memory acquisition and retrieval. (A) The protocol of auditory fear conditioning experiments with optogenetic inhibition of the PBN-PVT projection. (B–D) Quantification of freezing levels during condition trials (B), contextual test (C), and cue test (D), $n = 7$ mice per group. The yellow box indicated optogenetic inhibition. All data were represented as mean $\pm$ SEM, two-way ANOVA followed by Bonferroni test for B, C and D.

represented as mean $\pm$ SEM. Unpaired student's *t*-test for F, G, I, and K.

Figure 5-figure supplement 1. Calcium signals of PVT neurons in response to aversive stimuli. (A) Schematic showed injection of AAV2/8-hSyn-GCaMP6s into the PVT and placement of the optic fiber above the PVT. (B) Representative of GCaMP6s expression and the position of optic fiber in the PVT. Scale bar: 400 μ m. (C and D) The calcium signal of the PVT neurons (C) and the quantification of the average Ca^{2+} signal before and after footshock (D). The black bar represented the baseline period (B.s, -1 to -0.5 s), and the red bar represented the post-stimulus period (Post, 0.5 to 1 s), $n = 5$ mice. (E and F) The calcium signal of the PVT neurons (E) and the quantification of average Ca^{2+} signal before and after air puff (F), $n = 5$ mice. ** $p < 0.01$, all data were represented as mean $\pm$ SEM. Paired student's *t*-test for D and F.

Figure 6-figure supplement 1. Dual Fos staining detecting Fos protein and *fos* mRNA induced by laser stimulation and footshock. (A) Top: Schematic showed injection of AAV2/9-EF1 α -DIO-ChR2-mCherry into the PBN and placement of the optic fiber above the PVT of Vglut2-ires-Cre mice. Bottom: Time windows containing laser (20 Hz, 5 mW, 5ms) and shock stimuli (0.5 mA, 1 s, 30 times), separated by 60 minutes of the rest period. (B–D) Example of

Fos protein and *fos* mRNA expression in the PVT. Red fluorescence represented Fos protein induced by laser stimulus, and green fluorescence represented *fos* mRNA detected by in situ hybridizations. Arrows indicated double-positive neurons, Scale bar: 100 μ m. (E) The proportion of co-expression neurons over Fos protein-expressing cells and *fos* mRNA-expressing cells, $n = 5$ mice.

Figure 6-figure supplement 2. The response latency of PVT neurons to laser activation and footshock activation. (A) Response latency of laser-activated PVT neurons ($n = 23$ neurons). (B) The histogram of response latency of laser-activated PVT neurons (less than 14 ms, $n = 12$ neurons). (C) Response latency of footshock-activated PVT neurons ($n = 28$ neurons). (D) The histogram of response latency of footshock-activated PVT neurons (less than 14 ms, $n = 13$ neurons).

Figure 7-figure supplement 1. Distribution pattern of projection fibers of PVT_{PBN} neurons. (A) The illustration showed injection of AAV2/1-hSyn-Cre into the PBN and AAV2/8-EF1 α -DIO-EGFP into the PVT of *Rosa26-tdTomato* mice. (B) The representative image of EGFP and tdTomato-transduced neurons in the PVT. Scale bar: 200 μ m. (C–G) Distribution patterns of EGFP fibers in the PFC (C), CI (D), NAc (E), BNST (F), and CeA (G). PFC, prefrontal cortex; IC, insular cortex; CI, claustrum; NAc, nucleus accumbens core; BNST, bed nucleus of the stria terminalis; CeA, central nucleus of the amygdala; BLA: basolateral amygdala; ZI: zona incerta, Scale bar: 200 μ m. (H) Quantification of the fiber intensity in these brain regions, $n = 3$ mice.